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ABSTRACT 
Traumatic brain injury (TBI) is a common cause of death and disability. Unfortunately, TBI patients will be 
affected by secondary insults, such as hypoxia and increased intracranial pressure, which may lead to 
secondary brain injuries. Because of this, these patients are treated in specialized neuro-intensive care units 
(NICU) where the brain is monitored in order to prevent secondary lesion development. Cerebral monitoring 
is limited by its locality and more generalized markers to monitor the injured brain are warranted. Biomarkers 
have been introduced in the field of TBI, where they may be evaluated to examine potential 
pathophysiological processes. S100B, a primarily astrocytic protein, is the most studied serum biomarker in 
TBI, but other candidates exist. The aims of this thesis were to validate biomarkers toward long-term 
functional outcome, to evaluate the effect of biomarkers and a new global method of microdialysis in 
multimodal monitoring of NICU patients and in a translational methodology assess how biomarkers may 
facilitate in the damage analysis in a hypoxic-TBI animal model. 
In Paper I, a retrospective study including 265 NICU TBI patients, where S100B samples were acquired at 
admission and every 12 hours the first 48 hours after injury, we detected a significant, and independent, 
correlation between S100B levels and long-term functional outcome. The predictive capabilities increased 
sharply after 12 hours and remained high up to 36 hours after injury. S100B levels were only significantly 
correlated to pathology detected on computerized tomography (CT) and not to extracranial trauma. 
In Paper II, a retrospective study including 250 NICU TBI patients, we analyzed S100B samples acquired 
later than 48 hours after injury. We noted that secondary increases of S100B even as low as 0.05µg/L is 
sensitive and specific enough to detect radiological verified cerebral deteriorations, undetected by 
conventional monitoring. 
In Paper III, a prospective study including 14 NICU TBI patients, we monitored patients using microdialysis 
(MD) in flowing cerebrospinal fluid (CSF) for a more “global” overview of cerebral metabolism. We 
validated the method using conventional CSF samples, and found that the MD-CSF method yielded adequate 
results. Also, albeit a small sample size, we noted that lactate and pyruvate levels were significantly elevated 
in patients with an unfavorable outcome.  
In Paper IV, a retrospective study including 182 NICU TBI patients, we analyzed serum and CSF levels of 
Neurofilament light, a protein of axonal origin thus different from S100B. We showed that NFL levels 
significantly correlated independently to outcome, even in the presence of S100B. However, we could not 
correlate NFL levels to injuries visible on CT and magnetic resonance imaging (MRI). 
In Paper V, a preclinical study including 73 Sprague-Dawley rats, we analyzed how hypoxia exacerbates 
TBI. We detected increased neuronal death using immunohistochemistry and increased lesion size on MRI in 
the hypoxic animals compared to normoxic animals. A trend was found towards higher S100B levels in serum 
after 24 hours in the hypoxic group. Vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 
1-alpha (HIF1α) expressions were significantly increased in the normoxic group. 
In summary, the biomarker S100B provides important information towards long-term outcome, even more so 
than other known predictors of long-term outcome. Outcome prediction models including both S100B and 
NFL presents the highest explanatory variance, presumably by monitoring different pathophysiological 
processes. S100B is a valuable asset in the multimodal monitoring in order to detect secondary cerebral 
injuries and together with the MD-CSF technique; it could improve conventional NICU care with a more 
global approach. Hypoxic insults following TBI aggravate injury development and this pathophysiological 
process could presumably be monitored using S100B as an indicator of injury severity.  
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY OF TBI 
Globally, traumatic brain injury (TBI) is a major health problem (Ghajar, 2000, Corrigan et al., 2010), 
and the highest contributor to in-hospital trauma related mortality (Acosta et al., 1998). Being a 
common problem in high income countries today, a vast majority of TBI related morbidity and mortality 
(90%) affects low and middle income countries (Hofman et al., 2005). Historically, TBI has been the 
disease of the young population, being the most common cause of mortality up to 44 years of age 
(Jennett, 1996, Tagliaferri et al., 2006). The effects of TBI are extensive, not only for the affected 
patient but also for the next of kin, furthermore it results in a huge economic burden for society, 
resulting in increasing indirect costs for rehabilitation and social welfare (Corrigan et al., 2010, 
Gustavsson et al., 2011, Leibson et al., 2012). Moreover, demographics are changing with a 
subsequent increase in frequency of TBI among the elderly, increasing the already high morbidity in 
that affected patient group (Roozenbeek et al., 2013).  
In Europe, studies have shown that the hospital admittance of TBI is 235 per 100.000 (Tagliaferri et 
al., 2006), even if differences exist throughout nations. In Sweden the prevalence is relatively high, 
with an admittance of about 450 per 100.000 (Andersson et al., 2003, Styrke et al., 2007). Even if the 
incidence of TBI is high in Sweden, the vast majority of cases have been shown to comprise of mild 
TBI (97%) (Styrke et al., 2007). Thus, the mortality rate is quite low, Sweden has a median mortality 
rate of 9.5 per 100.000 being the lowest in the Nordic countries, lower than the European average of 
about 20 per 100.000 and the US of about 18 per 100.000 (Tagliaferri et al., 2006, Sundstrom et al., 
2007, Corrigan et al., 2010, Coronado et al., 2011). The global mortality rate for severe TBI has 
drastically decreased during the 20th century, but has remained unchanged since the 1990’s, and is 
presently around 20-35 % (Stein et al., 2010, Flynn-O'Brien et al., 2015). While traffic accidents still 
remains the leading cause globally for TBI (Hofman et al., 2005), the most common cause in Sweden 
are falls (55%), predominantly among the elderly, while traffic accidents being the most common 
cause for the young, in total contributing to 30% of all TBI cases (Jacobsson et al., 2007, Styrke et al., 
2007). 
1.2 THE PRIMARY BRAIN INJURY 
As external forces affect the brain, including meninges, parenchyma and surrounding vessels, 
structures obtain energy, resulting in injuries of different natures. These forces include 
acceleration/deceleration, blast-waves or objects impacting, or even penetrating, the cranium and 
distorting the brain tissue. The severity of the injury, and extent of the primary damage, is determined 
by the duration and intensity of these forces. These injuries will result in either focal injuries, including 
hematomas, lacerations and contusions, or diffuse injuries leading to cerebral swelling or axonal injury 
(Nortje and Menon, 2004). Intracranial mass lesions increase the intracranial pressure, hence 
increasing the risk for subsequent secondary brain damage, and ultimately brain death due to brain 
stem herniation. Usually, several different types of injuries are present at the same time in TBI 
patients, presenting a very heterogeneous challenge for the physician. 
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1.2.1 Focal traumatic injuries 
1.2.1.1 Cerebral contusions and traumatic 
cerebral hemorrhages 
Traumatic parenchymal lesions, or contusions 
(Figure 1), are common after severe TBI; a pooled 
incidence of 13-35% in severe TBI has been 
reported (Bullock et al., 2006a). Primarily, 
contusions are a result of mechanical forces 
damaging parenchymal blood vessels, leading to 
micro- and macroscopic hemorrhages. Contusions 
are usually present in the frontal and temporal 
lobes, due to movements of the affected brain 
tissue over irregularities of the scull base (Adams 
et al., 1980), but depending on the type of impact, 
they might be present in several areas of the 
brain. Traumatic parenchymal lesions often 
evolve, leading to a more extensive mass-effect 
(Servadei et al., 1995), and subsequently lead to 
secondary brain injuries, neurological deterioration 
(Bullock et al., 1989) and a worse outcome 
(Mathiesen et al., 1995).  
1.2.1.2 Subdural hematomas 
Subdural hematomas (SDH) are mass lesions 
located in the subdural compartment between the 
arachnoidea- and the dura mater (Figure 1), often 
as a result from tearing of bridging veins and other 
dural vessels and frequently in combination with 
other cerebral injuries. Pooled incidence has been 
shown to be 21% in severe TBI patients (Bullock 
et al., 2006c). SDH is more common in the elderly 
compared to the young population (Hanif et al., 
2009), presumably as a result of subdural veins in the aged atrophic brain are more vulnerable to 
straining, even in low energy trauma (Hanif et al., 2009, Evans et al., 2015). In older cohorts, the 
correlation between presence of subdural hematoma in unconscious patients and mortality has been 
shown to be as high as 57 - 90% (Seelig et al., 1981), with a marked increase if midline shift is large 
and the hematoma is not rapidly evacuated.    
1.2.1.3 Epidural hematomas 
An epidural hematoma (EDH) is located outside the neuro-axis (Figure 1), and is often the cause of 
the disruption of meningeal arteries (36%) (Servadei et al., 1989), predominantly the middle 
meningeal artery, but may also be caused by hemorrhage from the middle meningeal vein or other 
venous sinuses. Present in up to 9% of unconscious TBI patients, EDHs are most common among 
patients in their twenties, and are rarely seen in patients above 60 years of age (Bullock et al., 2006b). 
In unconscious patients, with severe TBI and anisocoria, or an EDH with a volume bigger than 30 ml, 
regardless of consciousness level, the EDH should be evacuated promptly in order to minimize further 
damage (Bullock et al., 2006b). EDHs have been correlated to better outcome when larger 
Figure 1 - Computerized tomography illustrating contusions, 
epidural hematoma (EDH), subdural hematoma (SDH), 
traumatic subarachnoid hemorrhage (trSAH) and cerebral 
edema. Magnetic resonance imaging (MRI) presenting 
diffuse axonal injury (DAI). Pathology is highlighted by white 
arrows. 
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retrospective cohorts have been analyzed (Maas et al., 2005, Nelson et al., 2010), possibly since if 
adequately treated, there is limited damage to the cerebral parenchyma.  
1.2.2 Diffuse traumatic injuries 
1.2.2.1 Traumatic subarachnoid hemorrhages 
Traumatic rupture of subarachnoid arteries and veins are among the most frequent pathologies found 
among TBI patients subjected to autopsy (Figure 1) (Freytag, 1963). In larger human materials, 
radiological evidence of traumatic subarachnoid hemorrhage (trSAH) is found in 39% – 52% 
(Eisenberg et al., 1990, Maas et al., 2005). trSAH has been described, by several studies, as one of 
the most important factors for an unfavorable outcome following TBI (Maas et al., 2005, Nelson et al., 
2010). The presence of trSAH is correlated to the development of secondary ischemic injuries 
(Harders et al., 1996). This is primarily due to arterial vasospasm, which is present in up to 30% of 
cases with trSAH, and is more common 4-15 days post TBI (Martin et al., 1997). As a result, 
inadequate cerebral perfusion subsequently develops, as has also been reported in several cases of 
spontaneous subarachnoid hemorrhage (Kassell et al., 1985). Different pathophysiological 
mechanisms could explain the connection between trSAH and vasospasm, including depolarization of 
smooth muscle cells (Sobey, 2001), endothelin release (Zuccarello et al., 1998), catecholamine surge 
(Ley et al., 2009) and prostaglandin-induced vasoconstriction (Armstead, 2006). While the calcium 
inhibitor nimodipine has been shown to decrease the risk of vasospasm following trSAH (Kakarieka, 
1997), more recent reviews have failed to show any beneficial treatment effects (Vergouwen et al., 
2006). 
1.2.2.2 Diffuse axonal injury 
First described in the 1940s (Rand and Courville, 1946), traumatic tearing of axons, also called diffuse 
axonal injury (DAI) (Figure 1), is a common pathology present in up to 70% in closed head injury 
cases (Skandsen et al., 2010). DAI has been suggested to be the result of mass effect differences 
between gray and white matter that in rotational injury will slither, and tear, during accelerations 
(Margulies et al., 1990), resulting in ripped axons. DAI has been graded, dependent on histological 
presentation: Grade 1, injury to subcortical areas and corpus callosum, Grade 2, with more sever 
hemorrhagic axonal damage in the corpus callosum, and Grade 3, additional hemorrhages in the 
rostral brain stem (Adams et al., 1989). When the neuron is damaged, the transport along the axons is 
altered with subsequent swelling, disrupting which results in a histologically characteristic “bulb” found 
at the site of disconnection (Christman et al., 1994, Pettus et al., 1994). Moreover, this axonal 
disconnection has partly been shown to be the result of secondary processes, primarily involving 
calcium influx, protease activity and subsequent degradation (Buki et al., 1999). Axonal swelling has 
been shown to commence a few hours after injury (Povlishock and Christman, 1995) but evidence of 
axonal pathology may be present as late as several month following injury (Blumbergs et al., 1994). 
Several studies have shown that the presence of DAI on CT, and MRI, is correlated to an unfavorable 
long-term outcome (Paterakis et al., 2000, Nelson et al., 2010). 
1.2.2.3  Cerebral edema 
Frequent after TBI, edema formation is caused by parenchymal vascular disruption and osmotic 
imbalance, increasing the amount of cerebral fluid content (Figure 1) (Unterberg et al., 2004). There 
are mainly two types of edema affecting the injured brain: Vasogenic and cytotoxic. The vasogenic 
edema is primarily caused by a vascular collapse affecting the endothelial cellular layer, thereby 
disrupting the integrity of the blood-brain barrier. Subsequently, an influx of osmotically active ions will 
accumulate water in the extravasal space (DeWitt and Prough, 2003). Cytotoxic edema is the result of 
cellular (neuronal, astrocytic, microglial) fluid influx in the CNS, caused by energy depletion, and 
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thereby ionic pump failure leading to an increased membrane permeability of osmotic substances 
(Stiefel et al., 2005). The latter type of edema is thought to be more common in TBI, even if both 
contribute to ischemic events and secondary injury development (Marmarou et al., 2006).    
1.2.3 TBI severity classification 
The brain injury will affect the patient’s clinical abilities. A more severe TBI may result in focal 
symptoms and loss of consciousness depending on the cerebral structures affected and the extent of 
the injury, while milder injuries may only lead to nausea, vomiting and headache. At the moment, 
several classification systems for describing the extent of the TBI exist. 
1.2.3.1 Glasgow Coma Scale 
The most widely used TBI 
classification is the Glasgow 
Coma Scale (GCS, 3-15), 
assessing the best verbal- (1-
5), motor- (1-6) and eye (1-4) 
response of the patient 
during physical examination 
(Table 1) (Teasdale and 
Jennett, 1974, 1976). The 
motor response, including 
pathological extension and 
flexion motoric patterns in the 
unconscious patients, 
reflecting extensive injury, is 
the component that best 
correlates to outcome (Ross 
et al., 1998, Brain Trauma, 
2000a). By using these 
clinical symptoms as 
surrogate markers of the 
brain injury severity, it is 
possible to grade a patient 
with a positive CT scan into 
severe (GCS 3-8), moderate 
(9-13) and mild (14-15) TBI.  
There are however inherent limitations to the GCS classification (Zuercher et al., 2009). A significant 
difference between pre-resuscitation GCS and in hospital GCS have been detected (Winkler et al., 
1984, Majdan et al., 2015), which is probably due to administration of sedatives, alcohol, drugs or 
other non-cerebral conscious altering events (Stocchetti et al., 2004), even if injury progression cannot 
be ruled out in individual cases. In some cases, intubation and craniofacial injuries make it impossible 
to adequately assess GCS. Also, the assessment of GCS has been shown to have a high intra-
individual difference among physicians, with many examiners providing GCS scores with low accuracy 
(Bledsoe et al., 2014).     
1.2.3.2  Reaction Level Scale-85 
Another clinical assessment score is the Reaction Level Scale 85 (RLS-85, 1-8), based on the GCS 
(Starmark et al., 1988a) (Table 1), is used nationally in Sweden. This system is better for assessing 
Glasgow Coma Scale   
Behavior Response Score 
Eye opening Spontaneously 4 
 To speech 3 
 To pain 2 
 No response 1 
Verbal response Oriented to time, place and person 5 
 Converses, may be confused 4 
 Inappropriate words 3 
 Incomprehensible sounds 2 
 No response 1 
Motor response Obey commands 6 
 Moves to localized pain 5 
 Flexion withdrawal from pain 4 
 Abnormal flexion 3 
 Abnormal extension 2 
 No response 1 
Total Score  3 - 15 
Reaction Level Scale 85   
Consciousness Response Score 
Conscious No delay in response 1 
 Drowsy or confused 2 
 Very drowsy, response to strong stimuli 3 
Unconscious Localizes and ward off pain 4 
 Withdrawal from pain 5 
 Abnormal flexion 6 
 Abnormal extension 7 
 No response 8 
Table 1 – Glasgow Coma Scale (GCS) and Reaction Level Scale-85 
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intubated patients, as well as patients with swollen eye-lids, not specifically accounting for the verbal 
or eye command, but grading the score from 1 (alert) to 3 (very drowsy or confused) and then 4 
(localizes pain) to 8 (no response to pain) for different levels of unconsciousness (Stalhammar et al., 
1988). However, this scoring system shares many similarities with the GCS, especially the motor 
score evaluation, even if RLS-85 has been shown to have better inter-observer agreement than the 
GCS score (Starmark et al., 1988b).  
1.2.3.3  Abbreviated Injury Scale 
Abbreviated Injury Scale (AIS) is another system, ranging from 1 (minimum) – 6 (maximum, fatal) for 
each injured organ system, including the cerebral injury (Greenspan et al., 1985). It was developed in 
1971 in order to aid motor vehicle accident investigators, and the score represents a relative risk of 
“threat to life”, for a standardized person. The system is based on radiological and clinical criteria 
which have been shown to correlate with outcome. A head AIS ≥3 is considered a severe head injury 
(Greenspan et al., 1985).    
1.3 SECONDARY BRAIN INJURY 
Following the initial injury, different pathophysiological processes will commence. These will develop 
over minutes up to days or weeks (and in some instances years) after the primary brain damage. The 
severity of the secondary brain injury will be determined by the intensity of these secondary insults 
during the treatment period (Masel and DeWitt, 2010). Some of the detrimental secondary injuries that 
may occur in the damaged brain include activation of potentially harmful genes, free-radical 
generation, calcium-related damage, release of excitatory amino acids, mitochondrial dysfunction, and 
neuro-inflammatory processes. Often, these processes interact in a synergizing manner, further 
impairing cerebral tissue, which may lead to secondary injuries, and subsequent permanent cellular 
death. 
1.3.1 The Monro-Kellie doctrine 
In general, the central nervous system (CNS) consists of three compartments; blood (venous and 
arterial) (10%), parenchyma and meninges, (80-85%) and cerebrospinal fluid (CSF) (5-10%). Since 
the cranium is an enclosed and incompressible space, the relationship between (CSF), blood and 
brain tissue must all remain in volume equilibrium and the sum of the compartments be constant. This 
means that if any of the contents within the cranial compartment should increase, as in hydrocephalus 
and development of hematomas and tumors, it will have a direct effect on the other constituents, 
which then have to compensate by a decrease in volume. This phenomenon was first described by 
Alexander Monro, and later confirmed by George Kellie, and is today referred to as the Monro-Kellie 
doctrine (Mokri, 2001). Using these compensatory mechanisms, primarily by decreasing venous blood 
flow and CSF, intracranial mass effects may increase in size to quite a degree before the reserves are 
exhausted, and the intracranial pressure (ICP) will increase. As the ICP increases, the cerebral 
perfusion pressure (CPP, being calculated as mean arterial pressure (MAP) minus ICP), essential for 
brain tissue oxygenation will decrease. To adjust for this, expanding mass lesions following TBI could 
be surgically evacuated. However, in the neuro-intensive care unit (NICU) there are other non-surgical 
treatments for increasing ICP. On the other hand, if the ICP is allowed to increase, the patient will 
eventuelly suffer from Cushing’s triad; an increased pulse pressure with a concomitant raised systolic 
blood pressure, irregular aspirations and bradycardia, as the cerebrum herniates towards vital centers 
in the medulla and brain stem, subsequently causing circulatory and respiratory arrest (Fodstad et al., 
2006).  
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1.3.2 Cellular pathophysiology 
Following the direct tissue damage, the immediate effect of the primary injury, will lead to a 
devastating environment for the perilesional tissue, not being able to meet blood flow- or metabolic 
demand. The substrate delivery collapses, creating a harmful acidic cellular environment with 
increased lactate concentration due to the anaerobic conditions, not adequate to sustain cerebral 
tissue. This failure leads to membrane depolarization and the release of neurotransmitters which will 
activate sodium- and calcium channels, henceforth causing an intracellular catabolic process leading 
to apoptosis or necrosis, of the CNS cells (Werner and Engelhard, 2007). 
1.3.3 Secondary insults 
During pre-hospital care and in the NICU, 
secondary events may occur that may 
exacerbate the primary injury (Miller et al., 
1978, Jones et al., 1994) (Table 2). Primarily, 
these insults may lead to subsequent hypoxic 
or ischemic damage to the already injured 
brain (Miller et al., 1978). Increased 
intracranial pressure is considered the most 
severe secondary insult and has been 
extensively correlated to unfavorable 
outcome, however specific limits are a question of debate (Jones et al., 1994, Signorini et al., 1999).  
1.3.4 Altered cerebral perfusion 
Under normal conditions, the cerebral blood flow (CBF) has been shown to be about 50mL per 
100g/min, providing that the CPP is adequate (Phillips and Whisnant, 1992). Studies have shown that 
both global and focal ischemic events occur following hypoperfusion in TBI, which effect long-term 
outcome negatively (Inoue et al., 2005). Similar to ischemic stroke, a CBF <15 ml 100g/min will lead to 
irreversible tissue damage in TBI (Cunningham et al., 2005a). Unfortunately, post-traumatic 
hypoperfusion is further facilitated by vessel distortion due to mechanical injury and auto-regulatory 
failure (Rodriguez-Baeza et al., 2003).  
On the other hand, cerebral hyperperfusion (CBF >55 ml 100g/min), resulting in hyperemia, is also 
common following TBI, resulting in unfavorable outcome (Kelly et al., 1996). This phenomenon, which 
is more common 1-3 days following trauma (Martin et al., 1997) may be as harmful as hypoperfusion, 
since an auto-regulatory mismatch may relate to vasoparalysis, hence an inability for the brain to 
control for the cerebral blood volume, which may lead to a life-threatening increase in ICP (Kelly et al., 
1997).  
1.3.5 Autonomic dysregulation and CO2-reactivity 
Cerebral vessels are dependent on chemo- and mechanical receptors to regulate blood flow due to 
metabolic demand (Rossanda and Vecchi, 1979). Thus, indicating a higher metabolic rate and 
subsequent blood flow if the pCO2 is high and a low blood flow if the pCO2 is low, something that may 
be manipulated using hyperventilation in order to manage ICP (Raichle and Plum, 1972). To provide 
an adequate cerebral perfusion, cerebrovascular auto-regulation and vascular CO2-reactivity, are 
important mechanisms to avoid the development of secondary injuries. Unfortunately, blood flow auto-
regulation, vascular variability to flow volume, is many times impaired in the injured brain, and may be 
so up to several days after injury (Lee et al., 2001, Hlatky et al., 2002). This supports the current 
therapy regimes in providing an adequate perfusion pressure to the injured brain in order to prevent 
the development of ischemia or hyperemia. However, the cerebrovascular CO2-reactivity remains 
Table 2 – Some of the secondary insults that TBI patient might suffer 
from in the NICU. 
Systemic insults Intracranial insults 
Hypoxia Cerebral hypoxia 
Hypotension Increased ICP 
Anemia Progression of hematoma 
Pyrexia Seizure 
Hyponatremia Vasospasm 
Hypoglycemia Derranged cerebral metabolism 
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more robust, only affected in the severe TBI, hence being possible to treat patients using 
hyperventilation (McLaughlin and Marion, 1996), especially in cases of hyperemia since 
hyperventilation has a more profound effect on the CBF than the ICP (Obrist et al., 1984). 
1.3.6 Cerebral metabolic dysfunction 
As an effect of the hypoperfusion and hypoxia in TBI, the cerebral metabolism and energy state will be 
altered in damaged tissue (Cunningham et al., 2005a), reflected by an inadequate substrate delivery, 
disturbed lactate:pyruvate ratio and affected glucose metabolism (Glenn et al., 2003), with a 
subsequent effect on outcome (Wu et al., 2004). This energy disturbance might lead to a 
mitochondrial dysfunction (Cheng et al., 2012), hence a decreased production of adenosine tri-
phosphate (ATP), and subsequent calcium overload in the mitochondria (Verweij et al., 2000). This 
will lead to further cellular damage, apoptosis and an impaired intracranial status. Also, increased 
concentrations of glucose (hyperglucolysis) in the injured brain might occur, exceeding the metabolic 
demand (Bergsneider et al., 1997), perhaps indicating seizure activity or a disturbed metabolic control 
of the injured brain. 
1.3.7 Cerebral Oxygenation 
The cerebral oxygen consumption during normal conditions is approximately 3.5 mL per 100 g/min, 
which is about 20% of the total oxygen consumption of the body, despite the brain accounting for only 
about 2% of the body weight in an adult. In the injured brain, there is a miss-match between oxygen 
delivery (decreased) and oxygen consumption (increased), leading to brain tissue hypoxia. A brain 
tissue oxygen pressure (PBtO2) >20 mmHg of is considered sufficient, and levels below 10 mmHg are 
considered harmful (Rose et al., 2006, Brain Trauma et al., 2007g). Low levels of PBtO2 result in 
ischemic lesions and consequently a worse outcome, even in patients that are hemodynamically 
stable (Stiefel et al., 2006).  
1.3.7.1 Hypoxia-inducible factor-1 alpha 
Hypoxia-inducible factor-1 alpha (HIF-1α), is a transcription factor that is involved in oxygen 
homeostasis (Wang and Semenza, 1995) and provides an adaptive response to the unfavorable 
conditions present during hypoxia (Singh et al., 2012). When oxygen saturation drops, HIF-1α triggers 
the up-regulation of several genes, which in severe hypoxia may result in activation of detrimental 
cellular pathways leading to apoptosis (Chen et al., 2007). However, in milder hypoxic states (Fan et 
al., 2009, Singh et al., 2012), it may promote neuro-protective effects including angiogenesis via the 
production of vascular endothelial growth factor (VEGF) (Liu et al., 1995), erythropoiesis via induction 
of erythropoietin (Wenger, 2002, Shein et al., 2005), mitochondrial function (Ebert et al., 1995) and 
cell survival (Lawrence et al., 1996).  
1.3.8 Blood-brain barrier disintegration in TBI 
Surrounding the vessels of the brain are tightly connected endothelial cells and astrocytes connected 
by tight junctions, making up the blood-brain barrier (BBB). The BBB is responsible for creating a 
highly restricted environment in the CNS as it regulates the entry of blood-borne metabolites and 
immune cells, regulating the cerebral environment with an influx of vital substrates and secretion of 
waste products. The astrocytic podocytes, covering the BBB, as well as migroglial cells and the 
basal cell membrane of endothelial cells are an essential part of the BBB transportation, connecting 
to parenchymal microvessels (Lassmann et al., 1991, Abbott et al., 2006). 
Following injury, there is a disruption of the vascular integrity, functional changes in the 
pericontusional area and an increased permeability of the BBB to high molecular weight proteins, 
such as albumin due primary to functional changes (Chodobski et al., 2011). Rat models of TBI 
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have revealed an increased permeability 4-6 hours after injury, with a secondary peak after 3 days 
(Shapira et al., 1993, Baskaya et al., 1997, Hicks et al., 1997), while in humans, elevated albumin 
quota (QA) between CSF:serum, is detected up to a week following TBI (Bellander et al., 2011). The 
disruption of BBB also results in edema development (Unterberg et al., 2004).  
1.3.9 The glymphatic system following TBI 
A route between the interstitial fluid of the brain, cerebrospinal fluid and venous outflow has recently 
been discovered, entitled the glymphatic system because of the connection between glial cells and 
aquaporin-4(AQP4)-dependent paravascular pathways (mimicking a lymphatic drainage from the 
brain) (Iliff et al., 2012). This para-arterial influx of CSF through the brain extracellular fluid (ECF) to a 
para-venous outflow has been suggested to be the main efflux of cerebral protein debris (Nedergaard, 
2013), and is driven by arterial pulsations (Iliff et al., 2013). 
TBI has shown to result in a lost perivascular polarization of AQP4 up to 28 days after injury (Ren et 
al., 2013), yielding a decreased outflow of tau proteins after TBI (Iliff et al., 2014). A recent study 
shows that the glymphatic system works independently from BBB integrity following brain injury and 
that proteins of cerebral origin predominantly drain through the glymphatic system from the injured 
brain (Plog et al., 2015). 
1.3.10 Excitatory amino acids and oxidative stress 
Glutamate is the most prominent excitatory neurotransmitter substance in the human brain (Faden et 
al., 1989), which, together with aspartate, is excessively released as a result of injury in the 
perilesional area (Bullock et al., 1998). The rapid increase affects cerebral cells, over-stimulating 
glutamate receptors, leading to an influx of osmotically active ions, primarily sodium and calcium 
(Floyd et al., 2005), triggering successive catabolic breakdown. Reactive oxygen species (ROS) 
(oxygen radicals including hydrogen peroxide, superoxides, nitric oxide and peroxinitrite) have been 
shown to generate oxidative stress in the pericontusional area following TBI, leading to vascular-, 
membrane-, protein- and genomic injury due to peroxidation (Lewen and Hillered, 1998, Bayir et al., 
2005, Chong et al., 2005, Shao et al., 2006).  
1.3.11 Coagulopathy in TBI 
The effect on the systemic coagulation following TBI has been previously reviewed (Harhangi et al., 
2008, Kurland et al., 2012, Zhang et al., 2012), and is a common issue in operating theatres and 
intensive care units worldwide.    
In healthy humans, clot formation 
and fibrinolysis are in balance as 
not to develop excessive 
hemorrhage or thrombo-embolic 
events (Bennett and Ratnoff, 
1972). The pathophysiology of TBI 
might lead to both a hyper- and a 
hypocoagulative state (Touho et 
al., 1986). To add insult to injury, 
activated endothelial factors 
(Sulfonylurea receptor 1, SUR-1) 
in border zones surrounding the 
contusions, may lead to cell death through hemorrhagic necrosis and structural failure of micro-
vessels (Simard et al., 2009, Patel et al., 2010). Also, the aggregative capabilities of thrombocytes are 
affected following TBI, with loss of the thromboxane A2-receptor function and/or an impairment of 
Figure 2 - The left picture reveals a small contusion and SDH, while the right 
shows a substantial progression of the intracranial hemorrhages (black arrow) in 
a patient suffering from TBI. 
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platelet cyclooxygenase (Nekludov et al., 2007). Even though this process is not fully understood, its 
effect has been suggested to come from circulating micro particles which affect the coagulative 
capabilities following TBI (Nekludov et al., 2014).  
1.3.11.1 Progressive intracranial hemorrhage  
After impact, the inflicted injuries will lead to hematomas and lesions that may progress in size over 
time (Alahmadi et al., 2010), which has been shown in up to 80% of TBI patients (Figure 2) 
(Chieregato et al., 2005). Because of this, many early CT-scans may provide a result that does not 
fully reflect the true size of the fully developed hematoma (Oertel et al., 2002), which is why a limit of 
90-120 minutes after injury has been suggested to perform radiological examinations to more 
accurately illustrate the extent of intracranial lesions (Oertel et al., 2002, Velmahos et al., 2006). 
However, while the evolution of an intracranial hemorrhage is usually an ongoing process early after 
injury, it may occur as late as 4 days following TBI (Kurland et al., 2012). If coagulopathy is detected 
(increased prothrombin time (INR), increased activated partial thromboplastin time (APT-T) and low 
platelet count), the risk of the patient to develop a progressive intracranial hemorrhage is increased, 
with up to 31% (Stein et al., 1992), and is correlated to an unfavorable outcome (Greuters et al., 
2011). In the IMPACT-material, where available, increased INR was found in 26% while low platelet 
was found count in 7% (Van Beek et al., 2007), both correlated with an unfavorable outcome.   
1.3.11.2 Post-traumatic cerebral infarctions  
Ischemic injuries, due to vascular 
complications such as mechanical 
compression,  thromboembolic 
events, venous stasis, or vasospasm 
in cerebral vessels are common in 
autopsy material from TBI patients 
(up to 90%) (Graham et al., 1978), 
and are seen in 10-20% during  and 
after treatment in patients suffering 
from TBI (Figure 3) (Mirvis et al., 
1990, Marino et al., 2006, Tawil et al., 
2008, Tian et al., 2008, Chen et al., 
2013). Thrombocytopenia, elevated 
APT-T and increased D-dimer are seen in patients demonstrating post-traumatic cerebral infarction 
(PTCI), suggesting disseminated intravascular coagulation (DIC) as a conceivable cause in some 
cases (Chen et al., 2013). PTCI have also been shown to affect major cerebral vascular territories, 
such as the middle cerebral artery or smaller cerebral vascular systems (Server et al., 2001), 
detrimentally altered by increased pressure and subsequent herniation by lobes against the rigid 
tentorium (Rothfus et al., 1987), common for the posterior cerebral artery vascular territory (Ham et 
al., 2011). Even with aggressive decompressive treatment, the outcome for these patients are 
generally unfavorable (Ham et al., 2011). PTCI may also occur due to vasospasm as a consequence 
of trSAH (Kakarieka, 1997). 
1.4 CEREBRAL INFLAMMATION FOLLOWING TBI 
The brain has long been considered a privileged organ in concern to systemic inflammatory reactions, 
being surrounded by a shielding blood-brain barrier regulating the metabolism and flow of substrates, 
and being protected by its own immune system, consisting primarily of microglial cells (Benarroch, 
2013). However, the last decades have shed new light on the complex mechanism of neuro-
inflammation, being involved in a number of diseases, including, among others, multiple sclerosis 
Figure 3 - The left picture shows an injured brain following surgery. The right 
picture shows the same patient developing a post-traumatic cerebral infarction 
of the left hemisphere, as indicated by the white arrow. 
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(MS) (Xiao and Link, 1999). The inflammatory response to TBI has been reviewed extensively 
(Morganti-Kossmann et al., 2001, Morganti-Kossmann et al., 2002, Ziebell and Morganti-Kossmann, 
2010, Helmy et al., 2011b, Woodcock and Morganti-Kossmann, 2013), highlighting both beneficial and 
detrimental effects of the neuro-inflammatory response following TBI. 
1.4.1 The innate immune system in TBI 
Being unspecific to pathogens, the innate immune system is comprised of physical barriers, 
inflammatory cells, anti-bacterial peptides, complement proteins and cytokines, protecting the human 
body. A disruption of the BBB will lead to a facilitated transport of cells and inflammatory proteins to 
the brain parenchyma. It is important to note that the inflammatory cascade is complex, with probably 
several unknown interactions between involved immunological agents that have yet to be identified. 
1.4.1.1 Cytokines 
Cytokines are short-lived, small signaling proteins that form a multifaceted network of inflammatory 
processes, being both pro- and anti-inflammatory. A recent review have shown that Interleukin (IL)-1 
beta, IL-6, IL-8, IL-10, tumor necrosis factor alpha (TNF-A), all potent mediators of inflammation, are 
increased in response to the severity of the traumatic brain injury, suggesting a major role of the 
innate immune system in TBI (Helmy et al., 2011b, Woodcock and Morganti-Kossmann, 2013). 
Measurements of intracranial cytokine levels using the microdialysis (MD) technique reveal a temporal 
patterns in humans (Helmy et al., 2011a), presumably highlighting an ongoing role in the 
pathophysiology of TBI. 
1.4.1.2 Neutrophil granulocytes  
Immediately following TBI and disruption of the BBB, neutrophil granulocytes, the most abundant type 
of white blood cell, will infiltrate the cerebral tissue (Holmin et al., 1995, Holmin et al., 1998), a 
transport facilitated by chemotaxins (CXCL1) (Szmydynger-Chodobska et al., 2009) and activated 
vascular adhesion molecules (ICAM-1) (Carlos et al., 1997). A reduction of neutrophils in the brain 
parenchyma is possible to achieve using a soluble human recombinant complement receptor SCR1, 
and has been shown to correlate to less edema formation and tissue loss, probably due to the 
cytotoxic nature of granulocytes (Kenne et al., 2012). The concentration of neutrophils start to 
increase adjacent to the injury immediately to 24 hours after trauma (Al Nimer et al., 2013, 
Schwarzmaier et al., 2013), and has been shown to increase up to 7 days following injury, and 
thereafter steadily decline (Holmin et al., 1995, Bellander et al., 2010). 
1.4.1.3 Macrophages  
Macrophages have been shown to swiftly (within 12 hours) migrate to the injured area in the CNS 
following injury (Zhang et al., 2006), and to be able to phagocyte tissue debris and promote 
regeneration (David et al., 1990), thus having beneficial effects in the injured CNS. However, 
macrophages have also been shown to release different cytokines in the perilesional tissue (Turtzo et 
al., 2014), promoting inflammation and increase tissue loss (Lehrmann et al., 1997). The peak 
migration of macrophages have been seen in the lesion area 7 to 14 days after injury (Bellander et al., 
2010), exacerbated by diffuse traumatic hypoxic injury (Hellewell et al., 2010). 
1.4.1.4 Complement system activation 
The complement system, a highly regulated cascade of the innate immune system, has also been 
shown to play an active role in TBI (Stahel et al., 1998, Helmy et al., 2011b, Brennan et al., 2012).  
These immunological active molecules are predominantly synthetized in the liver, and are involved in 
agglutination of pathogens, chemotaxis, opsonization and direct lysis of cells, having an active role in 
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both the innate and adaptive immunological response to TBI. The complement system is triggered, 
and activated, by three distinct pathways; the classical pathway (by the factor C1 and C4, because of 
immunoglobulin (Ig) M or G binding), the alternative pathway (by the factor C3) and the lectin 
pathway. The following cascade of chemotaxis, and opsonization, substances is tightly regulated, 
ending up with C5b9, the Membrane Attack Complex (MAC), which will cause a lysis of cells (for 
review, see (Ricklin et al., 2010)). C1q, C3, C4, C3b, C3d and C5b9 all have been noted to be 
upregulated in the border zone surrounding contusions in human TBI (Bellander et al., 2001), 
indicating it to have an important role in the evolving injury process. Moreover, in the CSF, C5b9 is 
elevated following TBI (Stahel et al., 2001) and has been correlated to increased intracranial pressure 
following severe TBI (Bellander et al., 2011). In an in vitro model, C1q and C5b9 and have been 
shown to be upregulated in the perilesional area for up to 7 days after experimental injury in the 
absence if circulatory blood (Bellander et al., 2004a). The MAC is more prominent in the secondary 
injury development in focal injury, compared to diffuse axonal injury (Rostami et al., 2013). Also, by 
pharmaceutically inhibiting MAC, using a C6 antisense oligonucleotide, an increased neuronal and 
axonal survival has been seen following TBI (Fluiter et al., 2014). 
1.4.1.5 Microglia 
Being the primary immune cell in the CNS in mediating response to infection and injury, microglia 
plays an important role in TBI migrating to the damaged area, forming a line of defense to protect 
surviving cerebral tissue (Cunningham et al., 2005b, Davalos et al., 2005). The up-regulation of 
microglia is 1-3 days after TBI, but has been shown to continue up to 28 days (Bellander et al., 2010). 
Moreover, studies in humans have shown an increased microglia and macrophage activity up to 1 
year after injury, indicating an ongoing immunological process (Smith et al., 2013), a pro-inflammatory 
condition that might be chronic (Ramlackhansingh et al., 2011). Also, hypoxia has been seen to 
aggravate the microglial response to injury in neonatal rats (Leonardo et al., 2008). 
1.4.2 Adaptive immune response in TBI 
While originally being considered immune-privileged, we today know that several diseases in the CNS 
are dependent on the adaptive immune system (Xiao and Link, 1999) and the severity has been 
connected to the amount of infiltrating T-cells (McGavern and Truong, 2004). It has been suggested 
that the brain injury itself creates an early low-grade MS lesion, albeit the extent, and the role of the 
adaptive immune system in TBI, are not fully understood (Ling et al., 2006). CD4-positive and CD8-
positive, regulatory and cytotoxic T-cells, have been shown upregulated in the proximity to traumatic 
contusions 3 to 5 days following TBI and are thought to be involved in the ongoing, inflammatory 
cerebral response (Holmin et al., 1998).  
1.4.3 Cellular death in TBI 
The primary brain injury will lead to an immediate loss of viable cerebral tissue. However, the ongoing 
secondary injury cascade may lead to a subsequent development of cellular death in the CNS (Zhang 
et al., 2005, Stoica and Faden, 2010), up to a year following TBI (Williams et al., 2001). The dominant 
forms of cellular death described in TBI are mainly apoptosis and necrosis, while autophagic cell 
death and necroptosis also have been identified.  
1.4.3.1 Necrosis and necroptosis 
Immediately following trauma, necrosis occurs, as cell dies due to ischemic and mechanical tissue 
damages resulting in karyolysis and cell swelling (Fink and Cookson, 2005). The cell dissolves and 
different cytotoxic proteases and peroxidases will be released and thus further aggravate the cytotoxic 
environment in the injured tissue (Trump et al., 1997). A special kind of controlled necrosis has been 
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described, labeled necroptosis, characterized by a morphologic death similar to necrosis (energy 
independent) yet regulated by Necrostatin-1 (Degterev et al., 2005, Li et al., 2008). 
1.4.3.2 Autophagy 
Autophagic death, a degradation of cellular organells and proteins in cells during intense stress, have 
been detected up to 24 hours after TBI (Liu et al., 2008), and contributes to outcome in animal TBI 
models (Luo et al., 2011). Autophagic cell death may be present at the same time as apoptosis 
(Uchiyama et al., 2008), but has been suggested more neuro-protective since it maintains a cellular 
hemostasis yet is energy dependent unlike necrosis. However, if the energy is depleted during the 
autophagic process, necroptosis will occur instead (Amaravadi and Thompson, 2007).   
1.4.3.3 Apoptosis 
Apoptosis, was first described 1972 as a programmed cell death presenting morphological changes, 
nuclear condensation, vesicle formation and cell shrinkage, and eventually phagocytosis by 
macrophages (Kerr et al., 1972). Its role in TBI has been thoroughly reviewed (Raghupathi et al., 
2000, Wong et al., 2005). Apoptosis may be activated through several different pathways, the 
consecutive activation of caspases (primarily caspase 3), through either the activation of “death 
receptor” ligation (extrinsic pathway) or mitochondrial disruption (intrinsic pathway) (Eldadah and 
Faden, 2000). While perilesional cortical neurons are susceptible to secondary injury mechanism, with 
an increased apoptotic frequency days after trauma, thalami and hippocampal neurons are also 
sensitive to apoptosis, which have been shown in several animal- (Nawashiro et al., 1995, Clark et al., 
1997a, Bramlett et al., 1999b) and human studies (Kotapka et al., 1992, Ross et al., 1993), probably 
due to their high metabolic rate and substrate demand. Several drugs, primarily caspase inhibitors, 
have been proposed as potential therapeutic targets following TBI in order to limit the extent of 
apoptosis in experimental models (Eldadah and Faden, 2000), none has yet shown an improved 
clinical outcome in human TBI. 
1.5 ANIMAL MODELS OF TBI 
Patients being admitted for TBI present with various injury severities, different injury types, different 
ages and sex, genetic backgrounds and often with multiple trauma of extracranial origin. This 
heterogeneity makes it difficult to generalize findings and to perform clinical trials. To better reproduce 
the different conditions present at impact, animal models (using primarily rodents) have been created 
that mimic the affecting forces and settings, hence being able to monitor pathophysiological processes 
in TBI. However, the transition from animal to human models and trials has been shown to be difficult, 
presumably due to inherent discrepancies between species (Bullock et al., 1999), partly due to 
metabolic and age differences (Sengupta, 2013).   
1.5.1 Focal TBI models 
1.5.1.1 Weight drop device 
By dropping a free falling weight on to the exposed brain, a contusion type injury is formed (Feeney et 
al., 1981). The severity can be adjusted, using different weights and heights, however it has seen to 
cause “rebound” injuries from the falling weight which is a limitation and makes it difficult to control the 
reproducibility. Nevertheless, it is easily accessible and is fairly cheap, making it a common rodent 
brain injury model. 
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1.5.1.2 Controlled cortical impact 
A controlled cortical impact (CCI) uses a device to impact the cortex of brain during a controlled 
fashion, and might be considered an upgrade from the drop-device and fluid percussion injury models 
(Dixon et al., 1991). Usually, the CCI impact is performed on an area adjacent to the midline. A 
computer controlled piston will impact the exposed dura, with velocity, severity and depth of injury 
determined by the user (Gilmer et al., 2009). In comparison to the fluid percussion injury, the CCI 
injury is more focal. 
1.5.1.3 Penetrating brain injury 
Missiles, gunshots and other sharp objects may result in penetrating brain injuries (2001). Historically, 
large animal models have been used to mimic these conditions (Crockard et al., 1977). Today, small 
animal models of penetrating brain injury, where a sharp metal object penetrates the brain, have been 
well described regarding lesion size, edema and neuro-degeneration (Plantman et al., 2012, Cernak 
et al., 2014). Like the CCI, the penetrating brain injury is considered a focal injury. 
1.5.2 Diffuse TBI models 
1.5.2.1 Fluid percussion injury 
In order to create an experimental brain concussion, a state frequently observed in the more common 
mild TBI, the fluid percussion device has been suggested (Sullivan et al., 1976). After having 
performed a craniectomy around the midline (or more laterally) and exposed the dura, a cylindrical 
reservoir saline reservoir is attached. A strike at the other end of the cylindrical reservoir creates a 
pressure pulse which will travel to the intact dura and result in cerebral deformation. The injury has 
been shown to mimic a contusion injury as well as to have a diffuse injury pathophysiology 
(Thompson et al., 2005). 
1.5.2.2 DAI-models of injury 
DAI is the result of accelerations of the brain parenchyma, due to mass effect discrepancies which will 
tear and damage axons. In order to mimic these circumstances in a rodent, without hemorrhages or 
focal injuries, several models have been developed (Marmarou et al., 1994, Cernak et al., 2004, 
Davidsson and Risling, 2011). The most common models used are variations of the model described 
by Marmarou et al where a disc is being attached to the head of an animal, where later on a weight is 
dropped, hence resulting in an impact that will yield axonal injuries in the brain stem, corpus callosum, 
basal ganglia and subcortical tracts (Marmarou et al., 1994).  
1.5.2.3 Blast injury 
Improvised explosive devices, and conventional weapons, create blast injuries which through a shock-
wave will injure the brain (Langlois et al., 2006). These blast injuries create diffuse injuries, similar to 
the diffuse axonal injuries, and have been reproduced in detail in animal models following shock-wave 
injuries (Risling et al., 2011, Gunther et al., 2014). 
1.6 TBI MANAGEMENT 
1.6.1 Pre-hospital management 
In order to provide an optimal treatment immediately after injury to TBI patients, evidence based 
management, resuscitation and central nervous system protection, should be initiated at the scene of 
accident (Badjatia et al., 2008). Secondary insults, if present at the scene of accident, have been 
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shown to lead to the development of secondary injuries and negatively affect patient outcome (Cooke 
et al., 1995, Stocchetti et al., 1996).  
1.6.1.1 Hypotension 
A low blood pressure, hypotension, due to hypovolemia, decreased cardiac output or other systemic 
dysfunctions, might lead to an inadequate cerebral perfusion. If the brain does not sustain a 
satisfactory blood flow, it may lead to insufficient substrate and oxygen delivery, which in turn may 
result in tissue ischemia.   
Studies have shown that a cut-off of <90 mmHg systolic blood pressure, at the scene of accident on 
patients suffering from TBI, is independently correlated to an unfavorable outcome (Chesnut et al., 
1993, McHugh et al., 2007b). Between 18%, up to 35%, of TBI patients suffer from pre-hospital 
hypotension, presumably as a result of concomitant injuries (Chesnut et al., 1993, McHugh et al., 
2007b).  
1.6.1.2 Hypoxia 
A decreased level of oxygen saturation in the brain parenchyma, cerebral hypoxia, may be the result 
of an obstructed airway, respiratory failure or any other damages to the lungs or associated vessels. 
Also, a lower surrounding oxygen pressure, used in models of hypoxic TBI, will mimic the conditions 
present during pre-hospital hypoxic situations. 
Studies have shown that  20% - 45% of TBI patients suffer from pre-hospital hypoxia (Jeremitsky et 
al., 2003, McHugh et al., 2007b), a condition which subsequently has been shown to correlate with 
worse outcome in humans (Jones et al., 1994, Chi et al., 2006, McHugh et al., 2007b, Yan et al., 
2014). A cut-off of 90% oxygen saturation, and airway obstruction, are often defined as significant pre-
hospital hypoxia. Hypoxia may lead to cerebral ischemia, an irreversible secondary brain injury 
frequently seen in autopsy materials of TBI patients (Graham et al., 1989). In experimental conditions, 
hypoxic TBI seems to lead to an exacerbated cerebral inflammation (Hellewell et al., 2010, Yan et al., 
2011), an aggravated neuronal death and lesion size (Yamamoto et al., 1999, Matsushita et al., 2001, 
Gao et al., 2010, Hellewell et al., 2010), and having a detrimental effect on the BBB and edema 
formation (Ishige et al., 1987, Tanno et al., 1992, Van Putten et al., 2005, Yan et al., 2011), as well as 
leading to worse functional outcomes (Ishige et al., 1987, Clark et al., 1997b, Bramlett et al., 1999a, 
Hallam et al., 2004, Hellewell et al., 2010, Yan et al., 2011).  
1.6.1.3 Combination of hypoxia and hypotension 
Patients that suffer from both low blood pressure and oxygen saturation at the scene of accident are in 
greater risk of ending up with an unfavorable outcome (Miller et al., 1978, Chesnut et al., 1993, 
McHugh et al., 2007b). Of the two, hypotension has been shown to be better correlated with poor 
outcome (Manley et al., 2001), perhaps as an aggregate for more extensive and severe intracranial- 
and extracranial injury. In animal models, a general cerebral hypoxia has been seen to generate a 
systemic hypotension (Clark et al., 1997b, Bramlett et al., 1999a) perhaps indicating a greater co-
existence of the two secondary insults than what is commonly described.   
1.6.1.4 Hypothermia 
Patients suffering from hypothermia at the scene of accident, present in about 10% of cases, more 
common during winter, have been seen to correlate to an unfavorable outcome to the same extent as 
hypoxia and hypotension (McHugh et al., 2007b, Tohme et al., 2014). This finding could partially be a 
result of extended time between the traumatic insult and the initial/or definitive care, potentially 
worsening secondary injuries. 
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1.6.2 Radiological examinations 
1.6.2.1 Computerized tomography 
The computerized tomography (CT) scan of the head was first introduced in the early 1970s 
(Ambrose, 1973, Ambrose and Hounsfield, 1973) but has since then been extensively modified and 
updated to become the important tool it is today for diagnosing neurological pathology. Due to its 
availability, speed and accuracy to detect acute cerebral conditions, it’s the modality of choice in the 
emergency setting (Wilson, 2009). Using a scanning X-ray tube circulating around the head, two 
detectors on the opposite side will absorb the radiation, as described by Hounsfield (Hounsfield, 
1973). The absorption will be dependent on the intensity of X-rays at the source and the intensity of X-
rays hit by the detector, air will not absorb any X-rays while tissue will absorb more. The amount of 
absorption is called Hounsfield units, where air has -1000, water 0, bone 500 to 3000, and brain 
parenchyma 20-45 (Ambrose, 1973, Hounsfield, 1973). Therefore, acute hemorrhages, and the bone, 
appear hyperdense while edema and ischemia hypodense as they contain more water (Ambrose, 
1973). Today, multi-detector CT (MDCT) scanners provide a rapid acquisition of several submillimeter 
axial-section data from a single gantry rotation, hence being able to reconstruct the injury into different 
2D and 3D pictures (Kubal, 2012), substantially improving the diagnostics of TBI patients. 
1.6.2.2 Magnetic resonance imaging 
The magnetic resonance imaging technique (MRI), or nuclear magnetic resonance as it was originally 
called, was developed by Lauterbur in 1973 (Lauterbur, 1973). MRI was later on introduced clinically 
in the 1980s and the different techniques associated with MRI have developed and improved 
tremendously since then. 
The principle behind MRI is to use radiofrequency pulses in a magnetic field which will excite 
hydrogen nuclei (protons) residing in water molecules in the body. The magnetic field and pulses may 
be modulated to acquire a spatially recorded image. Depending on the density of protons, there will be 
different intensity on images. Two different visualization protocols are often used, T1 and T2, 
depending on the time taken for proton relaxation. For instance, T2 is bright in areas with high water 
content (as in the CSF). Different techniques have developed over the years, including diffused 
weighted imaging (DWI), useful to detect edema and stroke (Lansberg et al., 2000, Unterberg et al., 
2004, Le and Gean, 2009), susceptible weighted imaging (SWI), to detect micro-hemorrhages in 
diffuse axonal injury (Haacke et al., 2009) and diffuse tensor imaging (DTI) to measure white matter 
integrity, hence axonal disruption (Basser et al., 2000, Shin et al., 2012). In DWI, the water diffusion 
rate is measured for every image element (referred to as voxels), making it interesting in pathologies 
where cellular environments are affected, such as edema and ischemia (Lansberg et al., 2000, 
Unterberg et al., 2004). Diffusion is then calculated in apparent diffusion coefficients (ADC) which 
measures differences of water content within the analyzed tissue (Sener, 2001).  DTI is similar to DWI, 
but is capable to detect and visualize homologous structures within the brain, such as axons, since the 
water content will diffuse more rapidly in the direction of the axonal structure. SWI detects 
susceptibility differences in the brain, following different image post-processes, making it very 
sensitive in the detection of iron deposits and hemorrhages. Another technique, called fluid attenuated 
inversion recovery (FLAIR), uses a protocol that nullifies fluid, thus making it possible to remove the 
effect of CSF, and may thus better visualize periventricular lesions present in e.g. multiple sclerosis 
(De Coene et al., 1992).     
MRI has better resolution than CT scans, and also a better contrast between gray and white matter, 
making MRI superior to CT scans in detecting edema (Unterberg et al., 2004), even differentiating 
them between vasogenic and cytotoxic, and ischemic injuries (Lansberg et al., 2000). However, the 
imaging technique is slower and more expensive, and not as accurate as CT to detect traumatic 
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subarachnoid hemorrhages (Snow et al., 1986) and fractures (Roguski et al., 2015), thus not readily 
an option in the emergency setting. 
1.6.3 Radiological grading of injury 
By examining large cohort of TBI patients, different protocols have been formed which may facilitate 
interpretation and prognostication of TBI.  
1.6.3.1 Marshall CT-score 
Today, the dominant scoring system 
used is the Marshall CT-score (Table 3) 
(Marshall et al., 1991). Generally, it is 
divided into no visible injury, diffuse- (3 
steps, depending on severity) and focal 
injury (any lesion >25 mm
3
) related to 
mortality and is based on patients in the 
extensive Traumatic Coma Data Bank 
(TCDB) study (Marshall et al., 1983). 
Moreover, “evacuated mass lesion” is 
also noted in the scale. They authors 
detected an increase in unfavorable 
outcome as the diffuse swelling 
exacerbated, suggesting it an indirect 
sign of increased ICP (Marshall et al., 
1991). However, later studies have 
revealed a limited capacity in outcome 
prediction using the Marshall CT-score 
compared to the Rotterdam- and 
Stockholm CT-scoring systems (Maas et 
al., 2005, Nelson et al., 2010).  
1.6.3.2 Rotterdam CT-score 
By using the Marshall CT-score 
variables, Maas et al pioneered the 
Rotterdam CT-score (Table 3) (Maas et 
al., 2005). This systems re-weights the parameters into a graded scale from 1 (best) to 6 (worse) 
where trSAH, basal cistern compression and midline shift (>5mm) are dichotomized as unfavorable 
parameters while the presence of EDH to have a favorable correlation towards outcome. EDH has in 
bigger patient materials been shown to be a positive predictor of outcome (Maas et al., 2007), 
presumably since in these patients, if treatment is rapidly provided, the brain parenchyma will remain 
relatively uninjured. 
1.6.3.3 Stockholm CT-score 
The Stockholm CT-score was introduced in 2010 and, in comparison to the other systems, uses a 
continuous scale to grade severity (Table 3) (Nelson et al., 2010). The scoring system uses the 
magnitude of midline shift, as an aggregate of all focal and diffuse lesions, although the presence of 
EDH is favorable, as well as its own grading of subarachnoid hemorrhage and is the only CT-scoring 
system to include DAI visible on CT scans as a negative predictor (Nelson et al., 2010).  
Marshall CT classification  
Diffuse injury I No visible intracranial pathology 
detected on CT scan 
Diffuse injury II Cisterns are present with midline 
shift of 0-5 mm and/or lesions 
densities present; no high or mixed 
density lesion >25 cm3 may include 
bone fragments and foreign bodies 
Diffuse injury III Cisterns compressed or absent with 
midline shift of 0-5 mm; no high or 
mixed density lesion >25 cm3 
Diffuse injury IV Midline shift >5 mm; no high or 
mixed density lesion >25 cm3 
Evacuated mass lesion (V) Any lesion surgically evacuated 
Non-evacuated mass lesion (VI) High or mixed density lesion >25 
cm3; not surgically evacuated 
Rotterdam CT score Increasing sum results in an 
increased risk of unfavorable 
outcome 
Basal cisterns 0 = normal, 1 = compressed, 2 = 
absent 
Midline shift 0 = ≤5 mm shift, 1 = >5 mm 
Epidural mass lesion 0 = present, 1 = absent 
Intraventircular/subarachnoid blood 0 = basent, 1 = present 
Final sum + 1 = Rotterdam CT score  
Stockholm CT score (tally) Increasing sum results in an 
increased risk of unfavorable 
outcome 
(Midline shift (in mm))/10 + (extent of subarachnoid hemorrhage)/2 - 1 (if 
EDH + 1 (if DAI) + 1 (if dual-sided SDH) 
Final sum + 1 = Stockholm CT score (tally) 
Table 3 – Describing the Marshall-, Rotterdam- and Stockholm CT scoring 
classification systems. 
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1.6.4 The neuro-intensive care unit – Multimodal monitoring 
The main goal with neuro-intensive care is to minimize the burden of secondary insults in order to 
prevent the development of permanent secondary injuries (Helmy et al., 2007). To improve the neuro-
intensive care, evidence based guidelines have been introduced by the Brain Trauma Foundation 
(BTF) (Brain Trauma, 2000a, Brain Trauma et al., 2007a), where departments that have adhered to 
these regimes have shown an improved outcome (Hesdorffer and Ghajar, 2007). These therapies aim 
to improve conditions by emphasizing intracranial monitoring, and the necessity to optimize cerebral 
perfusion and regulate intracranial pressure. By setting up clinically important threshold levels for 
blood pressure (Brain Trauma et al., 2007b), intracranial pressure (Brain Trauma et al., 2007f), 
cerebral perfusion pressure (Brain Trauma et al., 2007d), cerebral oxygenation (Brain Trauma et al., 
2007g) as well as evaluating current therapies, including hyperventilation (Brain Trauma et al., 2007j), 
hyperosmolar therapies (Brain Trauma et al., 2007c), anti-seizure prophylaxis (Brain Trauma et al., 
2007i) and nutrition (Brain Trauma et al., 2007h), it provides physicians with a robust tool to treat 
patients suffering from moderate and severe TBI.  
Other therapies exist, including the Swedish “Lund-concept”, which emphasizes, in contrast to the 
BTF-guidelines, that ICP reducing therapy should start immediately following admission, even during 
normal intracranial conditions, in order to maintain normal physiology in the injured brain, minimize 
future cerebral swelling, and hence prevent a potentially low CPP (Asgeirsson et al., 1994).  
1.6.4.1 Measuring Intracranial pressure 
The ICP, and thereby also the CPP, is commonly measured using a ventricular catheter (extra 
ventricular drain, EVD), being introduced in the 1960s (Lundberg, 1960). In cases where performing a 
ventriculostomy is not feasible, an intraparenchymal pressure device may be used, though they have 
been shown to have higher internal variation of ICP levels compared to EVDs (Brain Trauma et al., 
2007e). Many therapies are today focused on decreasing ICP, since increased levels, >20-25 mmHg, 
have been shown to negatively affect outcome (Brain Trauma et al., 2007f) . Surgical methods, 
removing space occupying mass lesions, are obvious in the acute care of TBI patients in order to 
decrease potentially fatal intracranial pressure. However, sedation using certain pharmaceuticals, 
mainly propofol, midazolam and barbiturates, have shown to decrease metabolic demand (Stewart et 
al., 1994), and to lower ICP (Eisenberg et al., 1988) (Nugent et al., 1982, Herregods et al., 1988). 
Moreover, hyperosmolar therapy, using mannitol or hypertonic saline (HTS) to osmotically extract fluid 
from the intracranial space, is used to decrease ICP, with HTS being suggested to be the new golden-
standard therapy (Marko, 2012). 
1.6.4.2 Measuring Intracranial blood flow 
It is possible to monitor the cerebral blood flow continuously using a surgically implanted cerebral 
thermal diffusion probe (TDP; Hemedex® Cambridge, Massachusetts, USA) (Vajkoczy et al., 2000), 
albeit only monitoring a very regional area. Transcranial Doppler (TCD), a non-invasive way to 
measure flow velocities in major cerebral vessels, is also used to detect intracranial vasospasm and to 
assess cerebral auto-regulation (Bouzat et al., 2014). 
1.6.4.3 Measuring brain oxygenation 
Approximately 25% of the patients suffering from TBI, and presenting normal ICP, still suffer from 
cerebral hypoxia (Stiefel et al., 2006). In order to monitor the PBtO2, it’s possible to surgically implant 
catheters in affected brain areas (LICOX®, IntegraLifeSciences, Plainsboro, NJ, USA or Neurotrend, 
Diametrics Medical, St Paul, MN) to make sure that the damaged brain does not suffer from hypoxia. 
Levels of PBtO2 below 15(-10) mmHg (Dings et al., 1998, Valadka et al., 1998) have been correlated 
to hypoxia, and an unfavorable long term outcome (Maloney-Wilensky et al., 2009), and should thus 
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be avoided. If PBtO2 decreases, it could be treated by decreasing ICP (or increasing CPP), or to 
improve systemic respiratory conditions. Hyperoxia is not recommended as it does not lead to an 
improved cerebral metabolism (Diringer et al., 2007), but instead impaired cerebral blood flow 
(Johnston et al., 2003) and worse functional outcomes in animal models (Liu et al., 1998), suggested 
to be a result of an increased oxidative stress and lipid peroxidation in the injured brain. 
By inserting a catheter into the internal jugular vein just below the scull base, it’s possible to measure 
the oxygenation of the blood leaving the brain hence providing an indirect measurement of cerebral 
oxygen consumption (CMRO2) (Schell and Cole, 2000). The technique is referred to as jugular bulb 
oximetry and is used in the NICU, especially during active hyperventilation. Excessive hyperventilation 
in order to treat intracranial hypertension has been seen to cause a significant decrease in PBtO2 
(Sarrafzadeh et al., 2003), thus prompting hyperventilated patients to be extensively monitored.  
While hyperbaric oxygen treatment has been seen to improve conditions following TBI (Rockswold et 
al., 2013), it’s still unclear which TBI patients that will best benefit from this type of treatment. 
Monitoring of cerebral oxygen pressure is important to continuously monitor for potential deterioration 
in the injured brain and should be used together with ICP-monitoring to improve patient outcome 
(Nangunoori et al., 2012). 
1.6.4.4 Measuring cerebral metabolism - Microdialysis 
In order to analyze focal brain biochemistry in patients suffering from TBI, the microdialysis (MD) 
technique has been used since the 1990s (Persson and Hillered, 1992). Using a semipermeable 
membrane, usually with pores the size of 20 kDa, substrates of the cerebral metabolism, including 
pyruvate, glutamate, glucose, glycerol, and lactate, may be measured in the extracellular fluid (ECF) 
of the brain parenchyma. The recovery of substrates, using the MD technique in ECF, has been 
shown to be around 70% (Hutchinson et al., 2000). High levels of lactate:pyruvate ratio, or isolated 
high lactate and low glucose (Hlatky et al., 2004), are presumably associated with cerebral ischemia, 
and correlated to an unfavorable outcome (Timofeev et al., 2011, Sanchez et al., 2013). Moreover, 
increased glycerol has been shown to correlate to phospholipid membrane degradation (Hillered et 
al., 1998), hence could be used as a surrogate marker of cellular damage. Guidelines have been 
introduced to better determine the use of cerebral microdialysis in the treatment of TBI patients 
(Bellander et al., 2004b).  
Presumably, the catheter should be placed in perilesional tissue, since this area is more susceptible to 
secondary injury, usually presenting higher lactate:pyruvate ratio and glycerol levels, thus is more 
crucial to monitor (Timofeev et al., 2011). Even if focal monitoring might be a strength, it is also a 
major weakness of the MD method since a lot is depending on the exact placement and location of 
the catheter (Hillered et al., 2005), resulting in highly individualistic patterns among different patients 
(Nelson et al., 2004), making the method difficult to generalize in treatment regimes. 
In an attempt to monitor the cerebral metabolism on a more global scale, including the entire brain, a 
“metabolic crisis” has been suggested, with simultaneous low glucose and elevated LPR, when the 
MD catheter is placed in uninjured brain tissue (Stein et al., 2012), which has been shown to correlate 
to an unfavorable outcome. Additional ways to monitor global cerebral metabolism are necessary to 
further improve detection of brain tissue at risk of secondary deterioration. 
1.7 OUTCOME MEASUREMENTS FOLLOWING TBI 
Good outcome measurements and predictions are essential for care providers to distribute resources 
more effectively, conduct better randomized trials in TBI, to balance benefits and risks of early 
treatment and to evaluate the effect of new therapeutic regimes. TBI poses a challenge when it comes 
to outcome prediction due to the inherent heterogeneity among its patient population, making it difficult 
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to detect independent factors associated with long-term functional outcome. In order to accumulate 
enough patients to find significantly independent parameters, multicenter studies are a necessity. 
Some of the multicenter trials in TBI are the IMPACT (International Mission for Prognosis and analysis 
of Clinical Trials in TBI) study (Marmarou et al., 2007b) and the CRASH (Corticosteroid 
Randomization After Significant Head Injury) study (Roberts et al., 2004, Perel et al., 2008).  
Several parameters have been found 
to correlate to poor outcome. The 
most important are increasing age 
(probably due to an increased 
morbidity, as indicated by Charlson 
co-morbidity index (Charlson et al., 
1987)) (Miller et al., 1981, 
Hukkelhoven CW et al., 2003, 
Mushkudiani et al., 2007, Vos et al., 
2010), low Glasgow Coma Scale 
score (GCS) (Stocchetti et al., 2004, 
Husson et al., 2010) and 
unresponsive pupil reaction 
(Marmarou et al., 2007a, Martins et 
al., 2009). Multivariate models also 
indicate that age, GCS motor 
response and pupil responsiveness, 
all explain outcome with a partial-R
2
 
of 3.5-6%, are the most important 
factors in predicting outcome after TBI (Murray et al., 2007).  
Today, the most common tool for functional outcome assessment following TBI is the Glasgow 
Outcome Score (GOS), pioneered in 1975 (Jennett and Bond, 1975) (Table 4). This grading consists 
of five levels where GOS1 = death and GOS5 = Good recovery. Usually, the GOS is assessed at 6 
months, but further functional outcome improvement has been seen up to >12 months (Corral et al., 
2007). GOS has been criticized for its broad use of “dependent” state (GOS3) and to improve this, the 
extended GOS (GOSe) was introduced in 1981 using 8 levels to better describe disabilities following 
TBI (Jennett et al., 1981). Other functional scales for assessment of outcome and disabilities after 
brain injury exist, including the Disability Rating Scale (DRS) (Rappaport et al., 1982), the Functional 
Independence Measure (FIM) and supplement Functional Assessment Measure (FAM) (Ottenbacher 
et al., 1996), all with more in depth interviews and questions corresponding to the patients quality of 
life. 
1.8 BIOMARKERS IN TBI 
A biological marker (biomarker) of injury is defined as “A characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (Biomarkers Definitions Working, 2001).  It 
may be proteins, or other substances, functioning as surrogate markers of injury. In several areas of 
medicine biomarkers play an important role, for instance the protein Troponin-T is used to detect 
myocardial infarction (Hamm et al., 1997) or D-Dimer to detect deep vein thrombosis (Wells et al., 
2006) and pulmonary embolism (Corwin et al., 2009). Ideally, a biomarker of brain injury should fulfill 
the following criteria (Kleindienst et al., 2007, Papa et al., 2008); 
 
Glasgow Outcome Scale/Score (GOS)  
5 Good recovery, resumption of normal life even if minor disabilities may persist. 
4 Independent, able to work in a sheltered environment due to disabilities but may 
independently use public transportation and manage personal hygiene 
3 Dependent, in need of daily support due to mental or physical disabilities 
2 Vegetative state, unaware of self and environment 
1 Death 
Glasgow Outcome Score Extended (GOSe) 
8 Upper good recovery Resumption of normal life with the capacity to work even if 
pre-injury status has not been achieved. Minor neurological 
or psychological deficits are allowed. If these deficits are 
not disabling then it is Level 8, if disabling then it is Level 7. 
7 Lower good recovery 
6 Upper moderate 
disability 
Patients have some disabilities and/or deficits of memory 
or personality but are able to take care of themselves. They 
are independent at home but dependent outside. If they 
are able to return to work even with special arrangement it 
is Level 6, if not then it is Level 5. 
5 Lower moderate 
disability 
4 Upper severe disability Patient who is dependent for daily support. If the patient 
can be left alone for more than 8h, it is upper Level 4, if not 
then it is Level 3. 3 Lower severe disability 
2 Vegetative state Unawareness, only reflex responses but with periods of 
spontaneous eye opening. 
1 Death  
Table 4 – Describing the two most frequently used assessments of long term 
functional outcome; Glasgow Coma Scale and the Extended Glasgow Coma 
Scale.  
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1. Demonstrate a high sensitivity and specificity for brain injury.  
2. A passive release from the CNS without any stimulated active release. 
3. Lack of specific effects on CNS cells interfering with the initial injury. 
4. Stratify patients by severity of injury.  
5. Have a rapid appearance in accessible biological fluids. 
6. An unlimited passage through the BBB. 
7. Provide information about injury mechanisms. 
8. Have well defined bio-kinetic properties.  
9. Monitor progress of disease and response to treatment. 
10. Predict functional outcome. 
Also, biomarkers might aid in the stratification of treatment, where it may serve as a companion 
diagnostics in order to guide treatment decisions in the dynamic clinical situation of neuro-intensive 
care. Today, no TBI biomarker candidate fulfills the criteria stated above yet several exist and aid 
physicians. The most studied biomarker of brain injury, with almost 800 publications on the subject 
(Pubmed®), is S100B. 
1.8.1 S100B 
The protein S100 was originally isolated from bovine brain almost 50 
years ago and got the name from its 100% solubility in a saturated 
ammonium sulfate solution (Moore, 1965). S100 is a small protein, 9-
14 kDa, present as different monomers but mainly as homodimers 
(Donato, 2001). It belongs to a family of intracellular, calcium-binding 
proteins predominantly present in astrocytes in the central nervous 
system (CNS), but several cells in the CNS and peripheral nervous 
system (PNS) express S100 (Steiner et al., 2007, Donato et al., 
2009). It exists mainly as the homodimer S100BB (Figure 4), or 
heterodimer S100AB in nervous tissue (Isobe et al., 1983, Haimoto 
et al., 1987). Together, these proteins make up the levels of what is 
usually referred to clinically as “S100B”. 
1.8.1.1 Different proteins of the S100 family 
The function of the proteins in the S100 family has been described in several review articles (Donato, 
2003, Kleindienst et al., 2007, Donato et al., 2013). Some notable functions include induction of pro-
inflammatory chemotaxis (S100A4, S100A8, S100A9 and S100A12) (Hofmann et al., 1999, Donato, 
2003, Meijer et al., 2012, Tong et al., 2014), increased malignancy risk (S100A4, S100A8 and 
S100A9) (Saleem et al., 2006, Srikrishna, 2012), regulation of allergy (S100A6) (Lesniak et al., 2009), 
neurite proliferation and neuronal survival (S100B, S100A1 and S100A4) (Huttunen et al., 2000, 
Novitskaya et al., 2000). 
1.8.1.2 Functions of S100B 
The biochemical properties of S100B have previously been thoroughly reviewed (Donato, 2001, 2003, 
Van Eldik and Wainwright, 2003, Goncalves et al., 2008, Michetti et al., 2012, Donato et al., 2013). 
Intracellularly, S100B is a part of the calcium hemostasis, thereby transferring signals from second 
messengers (Heizmann et al., 2002) but also involved in cell differentiation and cell cycle progression 
(Schafer and Heizmann, 1996). It has been shown to be able to inhibit apoptosis if applied in 
experimental conditions (Brewton et al., 2001). Extracellularly, S100B has been shown to have a 
neuro-protective properties as well as to promote neurogenesis (Haglid KG et al., 1997, Ahlemeyer et 
al., 2000), to be neuro-modulating and to promote neuronal plasticity (McAdory et al., 1998, 
Figure 4 - Homodimer structure of 
the S100B protein. ©Wikimedia 
Commons. 
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Nishiyama H et al., 2002), as well as to enhance processes involved in memory and learning (Fazeli 
et al., 1990, Kleindienst et al., 2013) if S100B is provided in both traumatic, and normal, conditions. 
The effect of S100B has been shown to be concentration dependent, where lower concentrations 
(nanomolar) are beneficial and higher concentrations (micromolar levels) are correlated to harmful 
effects (Rothermundt et al., 2003, Van Eldik and Wainwright, 2003). Increased extracellular levels of 
S100B may lead to neuronal dysfunction or cell death due to an inflammatory response that stimulate 
astrocytes and microglia to recruit and produce pro-inflammatory cytokines with a subsequent 
increase of the extracellular levels of calcium and activation of nitric oxide, with harmful effects (Hu et 
al., 1997, Koppal et al., 2001). The different effects of S100B has been suggested to depend on the 
receptor for advanced glycation endproducts (RAGE) which is upregulated by S100B levels and may 
cause pro-inflammatory gene activation (Donato et al., 2013). 
1.8.1.3 Release and elimination of S100B 
In vitro studies reveal that astrocytes, when affected by trauma or metabolic distress (Gerlach et al., 
2006), will release stored S100B, which has been measured extracellularly as fast as 15 seconds 
after a lesion is established (Willoughby et al., 2004). S100B mRNA concentration, as a sign of 
ongoing intracellular synthesis of the protein, will increase shortly after injury (Hinkle et al., 1997), thus 
the concentrations that is measured in blood is presumably both from secreted, and newly 
synthetized, origin.  
It is known that the concentration of S100B in the CSF could be up to 100x higher than in serum 
(Petzold et al., 2003). When the patient suffers from a TBI, the BBB will disrupt causing a leakage of 
proteins from the CSF with subsequent cerebral deterioration and edema formation (Marmarou, 
2003). The ratio of albumin between CSF:Serum (QA) is often used to quantify the degree of BBB 
disruption (Tibbling et al., 1977). Some authors claim that S100B is released into the serum through 
the disrupted BBB (Kapural et al., 2002, Kanner et al., 2003, Marchi et al., 2003), thus is a good 
marker of BBB permeability (Blyth et al., 2011, Lopez et al., 2012). However, the studies supporting 
S100B as a marker for BBB integrity are limited in sample size, use osmotic- or chemo therapy in non-
TBI patients to disrupt the BBB and are not focused on the complex BBB disruption present following 
traumatic conditions. Studies that do focus on TBI patients do not show any correlation between a 
disrupted BBB, using QA, and the peak serum levels of S100B (Bellander et al., 2011) or by using a 
ratio between CSF and serum S100B compared to QA (Kleindienst et al., 2010b), hence indicating a 
better correlation between actual injury and S100B levels, and not to the degree of BBB disruption. 
Furthermore, it has recently been shown that the glymphatic system, the drainage of CSF and ECF 
into the venous system, plays a very important role in the outflow of S100B from the CNS, 
independently from the BBB integrity, presumably explaining the findings in the TBI studies (Plog et 
al., 2015).  
Systemically, S100B has been shown to be excreted and eliminated 100% through the kidneys (Usui 
et al., 1989). Patients with renal failure, or renal impairment, have been shown to have increased 
S100B levels (Molina et al., 2002). Kidney transplanted patients have higher S100B levels, which also 
correlated to creatinine clearance (Gross et al., 2010), while another study could not detect any 
correlation between S100B levels and the glomeruli filtration rate (Jonsson et al., 2000). 
1.8.1.4 Half-life of S100B 
It is difficult to assess the half-life of S100B in serum after TBI since there will be a continuous release 
of the protein from the damaged brain, and perhaps a contribution from the CSF due to a disruption of 
the BBB (Kapural et al., 2002), outflow from through the glymphatic system (Plog et al., 2015), 
ongoing cerebral synthesis and/or active secretion (Hinkle et al., 1997, Gerlach et al., 2006). The half-
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life of S100B has shown to be everything from 132 minutes (Blomquist et al., 1997), 120 minutes 
(Ingebrigtsen and Romner, 1996, Jackson et al., 2000), 90 minutes (in melanoma patients) (Ghanem 
et al., 2001), 60 minutes (Ingebrigtsen and Romner, 2002) while another, more controlled method, 
puts it as short as 25 minutes (Jonsson et al., 2000), calculated from patients undergoing coronary 
artery bypass grafting not suffering from TBI. Nevertheless, compared to the other brain biomarkers 
NSE (20-48 hours) (Schmechel et al., 1978, Johnsson et al., 2000, Ingebrigtsen and Romner, 2002) 
and GFAP (in vitro 16-144 hours ) (Chiu and Goldman, 1984, Smith et al., 1984, Rolland et al., 1990) 
and UCH-L1 (11 hours) (Brophy et al., 2011) the half-life of S100B is significantly shorter, indicating 
that an elevation of S100B better designates a more imminent injury, and that the duration of the 
increase might correspond to the extent of the damage sustained.  
1.8.1.5 Extracranial sources of S100B 
There are known extracerebral sources of protein S100B, such as Langerhan’s cells, adipocytes, 
epithelial cells, cardiac and skeletal muscle cells and chondrocytes (Haimoto et al., 1987) and patients 
that suffer from trauma, presenting multiple injuries to the thorax, extremities and abdominal organs 
without any identified damages to the central nervous system have been shown to exhibit elevated 
S100B concentrations in serum (Anderson et al., 2001, Unden et al., 2005b, Routsi et al., 2006). 
However, S100B release of extracerebral origin appears to have a faster clearance than S100B 
released from the CNS (Pelinka et al., 2003, Savola et al., 2004, da Rocha et al., 2006) or even not to 
significantly influence the total serum concentration of S100B at all (Pham et al., 2010). Furthermore, 
probably due to its short half-life, S100B elevations seen in extra-cranial trauma are generally lower 
(median levels ranging 0.18 µg/l – 0.57µg/l) (Korfias et al., 2006b, Stalnacke et al., 2006) than those 
seen in TBI (mean levels ranging 1.7 µg/l – 4.01 µg/l) (Herrmann et al., 2001, Savola et al., 2004). 
While possible extracranial sources should be taken into consideration when assessing TBI patients 
(Persson et al., 2012), repeated sampling could perhaps exclude several of these confounding 
factors.   
1.8.1.6 Assays to analyze S100B 
There are several available assay kits to measure S100B used in the clinics and laboratories. An 
advantage of S100B is that it is stable, unaffected by storing and changes in temperature (Raabe et 
al., 2003a), which greatly facilitates the handling of the protein and reliability of the analyses. ELISA 
has become the golden standard in measuring S100B in laboratories, and are available from different 
manufacturers today (Diasorin, Sangtec, Italy; CanAG Diagnostics, Sweden; Roche Diagnostics, 
Swtizerland; Syn X Pharma Inc. Nanogen, USA) and usually measures “S100AB” and “S100BB”  
dimers as “S100B”. 
In clinical studies, the two most frequently used systems are the quantitative automated luminometric 
immunoassay, LIASON-mat S100 system (Diasorin, Sangtec, Italy) and the 
electrochemiluminescence immunoassay (Elecsys S100B®; Roche Diagnostics, Penzberg, 
Germany). The LIASON-system is primarily used to detect and screen for S100B in malignant 
melanoma and other tumors, thus is not manufactured for quick analyses (Mussack et al., 2006). The 
Elecsys system is increasing in popularity since it may analyze a sample faster and at a cheaper price 
(Smit et al., 2005).  
1.8.1.7 Clinical use of S100B 
The clinical properties of S100B in TBI have been thoroughly reviewed. (Korfias et al., 2006a, 
Bloomfield et al., 2007, Kleindienst et al., 2007, Kochanek et al., 2008, Filippidis et al., 2010, Schiavi 
et al., 2012, Astrand et al., 2013, Mercier et al., 2013).  
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Extracranially, S100B has long been used to monitor the advancement, and evaluate the efficacy of 
therapy, of melanocytic tumors (Kindblom et al., 1984, Smit et al., 2008, Egberts et al., 2009). Though 
lately, a clinical role has also been suggested in different cerebral conditions, including stroke (Foerch 
et al., 2004, Brea et al., 2009), global ischemia (Usui et al., 1989, Mussack et al., 2002), 
neurodegenerative disorders such as MS and Alzheimer’s disease (Rothermundt et al., 2003), as well 
as in cerebral herniation (Unden et al., 2004), spontaneous subarachnoid hemorrhage (Oertel et al., 
2006, Stranjalis et al., 2007, Sanchez-Pena et al., 2008, Moritz et al., 2010), and cerebral vasospasm 
(Oertel et al., 2006). However, it is in the field of traumatic brain injury where it has been mostly 
studied. The first human TBI study of S100B in serum was published by Ingebrigtsen et al. in 1995 
(Ingebrigtsen et al., 1995), though increased S100B levels in CSF following TBI had been previously 
described (Sindic et al., 1982). Later on, S100B was shown to be sensitive to detect a plethora of 
different intracranial lesions, including cerebral contusions (Raabe et al., 1998), subdural hematomas 
and traumatic subarachnoid hemorrhages (Romner et al., 2000), as well as epidural hematomas 
(Unden et al., 2005a). 
1.8.1.8 S100B in mild TBI in adults 
A vast majority (95%) of all TBI cases present as mild (Cassidy et al., 2004). In order to determine 
which patients that are at risk of developing, or are suffering from, intracranial hemorrhage, specific 
guidelines have been set-up to better select patients for CT investigations, such as the Scandinavian 
CT guidelines (Ingebrigtsen et al., 2000). Using the Scandinavian CT-guidelines, a sensitivity to detect 
an intracranial lesion is 96%, but the specificity is only 53% (Stein et al., 2009), resulting in 
unnecessary performed CT scans with excess, potentially harmful (Brenner and Hall, 2007), radiation 
and costs. The introduction of S100B testing in the emergency rooms, have introduced a way to 
potentially screen which patients that are in need of a CT scan. A recent meta-analysis on mild TBI 
and S100B, including 2466 patients from 12 scientific articles, states that the pooled negative 
predictive value (NPV) was more than 99% (CI 98%-100%) with a sensitivity of 97% in S100B 
detecting CT-visual brain pathology, using 0.10 µg/l as cut-off (Unden and Romner, 2010). With that 
sensitivity and NPV it makes S100B superior to, for example, D-dimer in detecting pulmonary 
embolism and deep vein thrombosis (NPV: 92%) (Wells et al., 2006) and Troponin-T (NPV: 96%) 
(Hamm et al., 1997) in detecting myocardial infarction. The authors, however, do stress the 
importance of acquiring the sample early after trauma and not to use it in patients with extracranial 
injuries or focal neurological deficits, since in these patients S100B is not enough to select patients for 
CT scans (Unden and Romner, 2010). This meta-analysis formed the foundation for the new 
Scandinavian guidelines for mild and moderate TBI (Unden et al., 2013). These guidelines assist the 
physicians and personnel in the emergency rooms to better determine which patients are in need of a 
head CT scan by acquiring a serum sample of S100B. If the concentration is less than 0.10 µg/L, 
within 6 hours after trauma, and the patient is suffering from a mild TBI without extracranial trauma 
and other risk factors, performing a head CT-scan could be reconsidered (Unden et al., 2013). It is 
estimated that this could reduce the number of unnecessary CT investigations by 32% in the 
emergency departments with more effective resource allocation.  
1.8.1.9 S100B in moderate-to-severe TBI 
As previously mentioned, several reviews have analyzed how S100B may be utilized in moderate and 
severe TBI patients. The latest review from 2013 includes a meta-analysis of 39 studies including a 
total of 1862 patients (Mercier et al., 2013). In this analysis, serum levels between 2.16µg/L to 
14.0µg/L predicted an unfavorable outcome (GOS1-3), while some included studies showed that 
similar levels are associated with mortality (Mercier et al., 2013). Comparable findings have led some 
authors to the conclusion that S100B could be used as a marker for facilitating brain death diagnosis 
(Egea-Guerrero et al., 2013, Shakeri et al., 2013).    
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However, the optimal time for collecting S100B to predict outcome after trauma in moderate-to-severe 
TBI has been a matter of intense discussions. In several studies, the initial sample of serum S100B 
after trauma is considered the most important for outcome prediction (Jackson et al., 2000, Romner et 
al., 2000, Petzold et al., 2002, Raabe et al., 2003b). Later time frames have also been suggested to 
have clinical significance, ranging from within 6 hours (Woertgen et al., 2002), 6 to 12 hours (Raabe et 
al., 2003b), within 12 hours (Muller et al., 2007), after 12 hours (Raabe et al., 1999), 24 hours 
(Gonzclez-Mao et al., 2011), within 42 to 79 hours (Herrmann et al., 2000), within 48 hours (Pelinka et 
al., 2003, Watt et al., 2006), 72 hours (Murillo-Cabezas et al., 2010) and finally up to >84 hours after 
trauma (Pelinka et al., 2003). It is becoming more and more obvious that the serum concentration of 
S100B itself is of limited use to predict outcome if the time that have lapsed since the trauma is 
unknown. Repeated sampling of S100B shows improved correlation towards outcome (Herrmann et 
al., 2000), even better than repeated radiological examinations (Gradisek et al., 2012). 
A study including pediatric TBI patients highlights the fact that the temporal profile, or trajectory 
analysis, of serum S100B concentration is of great importance since patients with increasing serum 
levels have a higher risk of unfavorable outcome compared to patients with subsequent serum 
concentrations in steady decline (Berger et al., 2010). These patterns have been seen in adult TBI as 
well, using trajectory analysis of repeated S100B CSF sampling, patients with worse outcome have 
high concentrations over a prolonged period time (Niyonkuru et al., 2013).   
1.8.1.10 S100B as monitoring marker of ongoing injury 
As studies have described scenarios where the levels of S100B continue to increase following TBI 
(Pelinka et al., 2003, Kleindienst et al., 2010a), there are some studies that have monitored patients in 
the NICU using subsequent samples of S100B. Raabe and co-workers monitored their patients, 
constituting mainly of those suffering from subarachnoid hemorrhages and post-operative intracranial 
tumor surgery, with daily S100B samples and found that an increase of S100B >0.5µg/L significantly 
correlated to the development of a severe secondary injury, such as a cerebral infarction or 
hematoma progression (Raabe et al., 2004). Moreover, they noted that a secondary increase of 
S100B influenced treatment in 21% of the cases. Another study by Undén et al revealed that 
increased levels of S100B were correlated to secondary neurological complications, in a material 
consisting primarily of spontaneous SAH patients (Unden et al., 2007), but the authors were not able 
to demonstrate that the secondary peak of S100B could predict these complications, nor were these 
complications associated with the long-term outcome. Other studies have shown a correlation 
between neurological deterioration with an increase of S100B during the NICU stay, suggesting it to 
be a useful therapeutic tool being closely related to pathophysiological mechanisms in TBI 
(Dimopoulou et al., 2003, Korfias et al., 2007, Hendoui et al., 2013). Several researchers have 
investigated the concentration of S100B as a surrogate marker for increased ICP and have found a 
correlation (Pelinka et al., 2003, Hayakata et al., 2004, Olivecrona et al., 2014). These findings 
strengthen the role of S100B as a laboratory test for monitoring patients admitted to NICU. 
1.8.2 Other biomarkers of brain injury  
There are other proteins of cerebral origin that have been elevated in serum following TBI (Yokobori et 
al., 2013, Chou et al., 2014), including myelin based protein (MBP) (Baker et al., 2009), microtubule-
associated tau proteins (C-tau) (Zemlan et al., 2002),  spectrin-break down products  (Farkas et al., 
2005, Mondello et al., 2010) and apolipoprotein-E (Kay et al., 2003). There are studies that propose 
that a combination of biomarkers following TBI, such as GFAP and S100B or UCHL-1 and GFAP, to 
further increase diagnostic capabilities and outcome predictions (Vos et al., 2010, Mondello et al., 
2012). NSE, NFL, UCHL-1 and GFAP are presented in short. 
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1.8.2.1 Neuron-Specific Enolase 
Neuron-specific Enolase (NSE) is the second most studied biomarker in TBI. NSE is an isoenzyme of 
enolase, a glycolytic protein that is present primarily in the cytoplasm of neurons and neuroendocrine 
cells (Marangos and Schmechel, 1987). Intracranially, it has been shown to be a biomarker of 
cerebral injury (Pleines et al., 2001, Cheng et al., 2014). Moreover, it may detect and monitor 
differentiation of specific cancers of neuronal origin (Herman et al., 1989). In axonal injury, NSE has 
been shown to upregulate in order to preserve cerebral homeostasis (Wu et al., 2004). The half-life in 
serum is over 20 hours (Ingebrigtsen and Romner, 2002). Unfortunately, NSE is present in 
erythrocytes, which limits its usefulness as a biomarker of brain damage as serum levels will be 
elevated if hemolysis occurs in the acquired blood sample (Johnsson et al., 2000). 
1.8.2.2 Neurofilament-Light 
Neurofilaments are the main components of the intermediate filaments that make up the axonal 
cytoskeleton. Neurofilaments consist of three chains, a heavy subunit (190-210kDa), an intermediate 
subunit (150 kDa) and a light subunit (68 kDa). The neurofilament-light (NFL) has, in situations of 
axonal damage, been seen to increase in biological fluids (Teunissen and Khalil, 2012). In 
neuroinflammatory diseases, such as amyotrophic lateral sclerosis and multiple sclerosis, NFL has 
emerged as a promising biomarker in CSF, where it may work as a surrogate therapeutic target and 
outcome of neurological disability and axonal damage (Tortelli et al., 2012, Gaiottino et al., 2013, 
Khademi et al., 2013). It is also increased in CSF following concussions in mild TBI, in the ECF of 
pericontusional areas in TBI and in the serum of patients with spinal cord injury (SCI). (Magnoni et al., 
2012, Neselius et al., 2012, Kuhle et al., 2014). The in-vivo half-life of NFL has been shown to be 
about 3 weeks (Barry et al., 2007).  
1.8.2.3 Glial fibrillary acidic protein  
Being a cytoskeletal filament protein present in astrocytes, glial fibrillary acidic protein (GFAP) was 
first identified in 1971 (Eng et al., 1971). It has been measured in serum and shown to be elevated in 
patients with head injury (Missler et al., 1999). Like S100, it’s an astrocytic protein, but since 
extracranial sources are limited, it has been suggested as more brain specific than S100B (Papa et 
al., 2014). Being considered a better marker for focal than diffuse brain injury (Pelinka et al., 2004), it 
has been used in ratios with neuronal markers (Ubiquitin C-Terminal Hydrolase-L1 (UCHL1)) in order 
to detect injury type in TBI patients (Mondello et al., 2012).  
1.8.2.4 Ubiquitin C-Terminal Hydrolase-L1 
Known as neuronal-specific protein gene product (PGP 9.3), ubiquitin C-terminal hydrolase L-1 (UCH-
L1) is present in the soma of neurons (Jackson and Thompson, 1981) and is involved in turnover of 
ubiquinated proteins set for internal metabolism in cells (Tongaonkar et al., 2000). In comparison to 
GFAP, it is more prominent in serum following diffuse brain injury than after focal injury (Mondello et 
al., 2011), providing additional information to clinical outcome, also when combined with other 
biomarkers of TBI (Mondello et al., 2012).  
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2  AIMS 
 
The general aims were to validate biomarkers collected in NICU TBI patients as predictors of long-
term functional outcome. Furthermore, in addition to conventional multimodal monitoring, analyze how 
biomarkers and CSF microdialysis may improve the detection of cerebral deterioration in TBI patients. 
Finally, through a translational approach, we aimed to analyze how biomarkers may assist in 
stratification of injury if hypoxia is added to the TBI. The aims of the individual papers were to; 
2.1.1.1 Paper I 
investigate S100B as an outcome predictor compared to, and adjusted for, other known parameters 
known to influence TBI outcome. Secondary aim was to examine which parameters that best 
correlated to serum concentrations of S100B. In addition, the optimal sampling time of S100B was 
investigated in relation to outcome prediction. 
2.1.1.2 Paper II 
study the occurrence of secondary increases in serum concentration of S100B and its association to 
possible pathological findings seen on neuro-radiological investigations. Additional aims were to 
identify what levels of secondary increases of S100B are optimal when monitoring TBI patients, and to 
relate secondary events and S100B fluctuation for monitoring secondary insults and outcome. 
2.1.1.3 Paper III 
validate a method of global MD monitoring by using a MD catheter placed in CSF. As a secondary 
aim, conventional CSF samples were used to calculate the recovery of the MD catheter and to 
correlate MD-CSF and MD-Brain parameters to patient outcome.  
2.1.1.4 Paper IV 
analyze a possible predictive value of CSF and/or serum NFL, as compared and adjusted to other 
known predictive factors including the two biomarkers S100B and NSE. Secondary objectives 
included to explore the dynamics of NFL levels after TBI in serum and CSF and to investigate if NFL 
and S100B reflect different pathophysiologic phenomena as analyzed by neuro-radiological 
examinations.  
2.1.1.5 Paper V 
to develop a hypoxic focal TBI rat model using controlled cortical impact. With the model, we aimed to 
investigate the effect of post-traumatic hypoxia on brain morphological changes including lesion 
progression and serum changes of the biomarker S100B, but also to vascular/cytotoxic edema, 
metabolic parameters (lactate), brain histopathological features such as neuronal survival, leukocyte 
and macrophage infiltration, all of which were compared to normoxic rats over 4 weeks. 
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3 MATERIAL AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
The studies were approved by the Regional ethical review board in Stockholm (Paper I, II, III and IV) 
or the Swedish department of agriculture (Paper V). The identification numbers are: 2009/1668-31/2 
(Paper I and Paper II), 2009/1112-31/3 (Paper III), 2014/2025-31 (Paper IV), N369/12 and N126/13 
(Paper V).  
At our department, every patient and next of kin receive information that they may be included in 
studies and quality follow-ups, and may voluntarily opt-out. For Paper I, II and IV no consent for 
participation was acquired due to the retrospective nature of the study. Furthermore, all data was 
anonymized and presented on group level making it impossible to identify unique patients. Paper III 
was a prospective study where informed consent was gathered from the next of kin, since the patients 
were unconscious when they were admitted the NICU. In case a patient decided later on that they did 
not want to participate in the study, they were withdrawn. The animal study, Paper V, was approved 
by the Department of Agriculture, and was performed in such a manner that animal suffering and 
morbidity were minimized. 
3.2 STUDY POPULATION 
The patients in the retrospective studies (Paper I, II and IV) had all been treated for severe-to-mild 
(GCS 3-15) TBI between 2005-2009 (I and II), and 2007-2013 (IV). All patients older than 15 years 
admitted to NICU were included in the studies. All admissions needed NICU care, approved by the 
attending neurosurgeon in charge. Following NICU admission, the patients were included in the 
Karolinska TBI database, a database administered by physicians at the NICU department and 
regularly updated by a NICU specialized nurse with extensive experience of TBI patients. Pre-
hospital-, admission-, and hospital parameters were gathered in conjunction with discharge data.  
Patients in Paper III, were also in need of NICU care and included in the TBI database, but the data 
and samples were prospectively collected during the NICU stay from 2010-2012. In contrast to Paper 
I, II and IV, only patients suffering from severe TBI (GCS 3-8 at admission) were included in this 
study.  
The animals in Paper V were all female Sprague-Dawley rats, being about 15 weeks old, weighing 
approximately 250 grams, on the day of surgery. 
3.3 OUTCOME ASSESSMENT 
For Paper I, II and IV patient outcome was assessed systematically at discharge from the hospital, at 
a follow-up visit at the department of neurosurgery and/or the department of neuro-rehabilitation 3-6 
months after discharge, and through a questionnaire regarding quality of life at about 12 months after 
discharge. Therefore, a combination of assessed and self-reported outcome was used. The final GOS 
score available for each patient, between 6 to 12 months after discharge, was used.  
For Paper III, a board-certified specialist in neuro-rehabilitation examined the patient 6 months after 
trauma during a follow-up visit assessing extended GOS. The extended GOS was dichotomized 
(Unfavorable GOSe 1-5 vs Favorable GOSe 6-8), as this correlated to current GOS scores for the 
patients (Unfavorable GOS 1-3 vs Favorable GOS 4-5).   
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3.4 TREATMENT 
3.4.1 Patient treatment 
For Paper I, II, III and IV, our department used the guidelines set forth by the Brain Trauma 
Foundation for treatment of patients suffering from TBI (Brain Trauma, 2000b, Brain Trauma et al., 
2007a), albeit with small modifications.  
All unconscious TBI patients were intubated, mechanically ventilated and sedated using morphine, 
propofol and/or midazolam.  Mass lesions, if detected, were evacuated as deemed appropriate by the 
attending neurosurgeon. ICP was measured predominantly using extraventricular drains (Medtronic, 
Fridley, MN, USA), or in cases where drain insertion was not possible, by intraparenchymal pressure 
monitors (Codman Microsensor, DePuy Synthes, Johnson&Johnson, New Brunswick, NJ, USA or 
Rehau AG+CO, Rehau, Germany). ICP was targeted at <20 mmHg and guided further treatment.  
MAP was continuously measured invasively, usually in the radial artery, and with transducers located 
at midlateral ventricular level. The head was slightly elevated at a 30 degree angle. CPP, calculated 
as MAP-ICP, was usually targeted at 50-70 mmHg. These targets were attained using intravascular 
infusions (primarily ringer’s acetate and albumin), vasopressors (norepinephrine) and osmotic therapy 
(hypertonic NaCl and, occasionally, mannitol). Intermittently, dynamic CSF drainage from ventricular 
catheters to reduce ICP was performed in Paper I, II and IV, but not in Paper III as they instead had a 
constant flow of CSF out through a CSF-pump.  
Mild hyperventilation and/or decompressive craniectomy were performed, if deemed necessary to 
improve intracranial conditions. If mild hyperventilation was deemed necessary for ICP control, it was 
guided using jugular bulbar saturation and venous-arterial-jugular lactate difference. Temperature was 
kept at 37°C, using paracetamol or external wrapping cooling systems. Mild hypothermia (35–36°C), 
was occasionally used for high refractory ICP. If ICP remained elevated despite all other measures, 
sodium thiopental was infused, limited by burst suppression and monitored with continuous 
electroencephalography. 
If clinically relevant traumatic subarachnoid hemorrhage (trSAH) was detected, nimodipine treatment, 
and monitoring with transcranial Doppler (TCD), was provided to reduce the risk of potential 
vasospasm and subsequent tissue ischemia. 
3.4.2 Animal treatment 
In Paper V, female Sprague-Dawley rats were used, 
housed in a 12-hour light/dark cycle, with food and 
water ad libitum. A room temperature of 21°C +/- 
1°C and normal air humidity were kept throughout 
the experiment. In the experimental procedure, the 
rats were anaesthetized using 5% Isoflurane, 
intubated, and mechanically ventilated using 2-3% 
Isoflurane as maintenance. Marcain® was provided 
as local anesthetic and Temgesic® and 
Paracetamol® for analgesia. Following a mid-line 
incision, a craniectomy, 8x5 mm, was performed revealing the dura. A 3 mm deep, 3 mm Ø wide, 
controlled cortical impact was made (Figure 5) (TBI 0310, Precision Systems and Instrumentation 
LLC, Lexington, KY, USA), followed by a 30 minute period where the rat inhaled either a hypoxic- 
(11%O2) or a normoxic (22%O2) air mixture. During this time period, the animals were monitored 
using a pulsoxymeter device (MouseSTAT™, Kent Scientific, Torrington, CT, USA) following by 
arterial blood gas sample from the tail artery (ABL800 FLEX analyzer, Radiometer Medical, Brønshøj, 
Figure  5 - Rat skull illustrating the performed craniectomy 
over the right hemisphere (box). The 3 mm in diameter 
wide impact hit in the middle of the craniectomy (black 
circle) (image in the public domain). 
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Denmark). Afterwards, the animals were allowed to regain consciousness on a heating pad, and then 
returned to their home cages. The procedure is explained in greater detail in Paper V.  
3.5 BIOMARKER ANALYSIS 
All human serum S100B samples were analyzed at Karolinska University Hospital Solna, Department 
of Clinical Chemistry. As per clinical routine in our NICU, since around 2006, serum samples of S100B 
are acquired at admission, and every 12 hours (06:00 and 18:00), as long as the patient remains 
unconscious. Before 2006, samples were acquired more sporadically, yet there were often samples 
during the first days of NICU admission. Except for venous serum samples acquired in the emergency 
room, all S100B samples were arterial. Arterial and venous samples have been shown to present 
similar results (Astrand et al., 2012). For Paper I, II, III and IV S100B, and NSE (Paper III and IV), in 
serum were acquired using the medical files from the hospital electronic charts system Take Care® 
(CompuGroup Medical Sweden AB, Farsta, Sweden) for each patient.  
In Paper I, the patients had at least one serum sample of S100B within the first 48 hours after 
reported trauma, and at least three samples within the first 72 hours. The S100B Area Under Curve 
(AUC) was calculated using ICU-Pilot® (mDialysis AB, Stockholm, Sweden). For sake of 
standardization, all S100B levels were set to 0 µg/L at time of trauma in the AUC calculations. The 
highest level of S100B, as well as AUC in the first 48 hours after the traumatic insult, were used. 
In Paper II, the patients had at least three serum samples of S100B acquired, where at least one 
sampled had to be obtained 48 hours following the trauma (Figure 6). Patient journals were scanned 
to detect potential “secondary peaks” of S100B. This peak was defined as an increase of serum 
S100B that developed more than 48 hours after the initial trauma. This time cut-off was arbitrary in an 
attempt to separate the primary S100B increase from the secondary peak. Three cut-off levels 
defining secondary peaks were investigated; 
≥0.05µg/L, ≥0.1µg/L and ≥0.5µg/L, persisting 
for at least 24 hours, thus not falling below the 
baseline serum concentration that existed 
prior to the increase.  
In Paper III, peak S100B concentrations in 
arterial serum, acquired between 12 to 36 
hours after trauma were used. NSE peak 
levels in the first 48 hours were included.  
In Paper IV, serum S100B concentrations at 
12-36 hours after injury as well as serum and 
CSF levels acquired concomitantly with NFL-
levels were used. For NSE, peak levels and 
levels acquired with NFL were used.   
In Paper V, after the animal had received a 
lethal dose pentobarbital, the heart was 
punctured using an angiocatheter (18G, KD Medical, Berlin, Germany) and blood was collected in two 
test tubes (2 x 1.5 mL test tube, 3810X, Eppendorf, Hamburg, Germany). The tubes were placed 
vertically for about 2 hours to allow separation. Afterwards, the blood was centrifuged 
(Spectrafuge16M®, Labnet International, Edison, USA) for 10 minutes at 10.000g (about 11.000 
rotations per minute (RPM)). The serum was collected and immediately frozen at -80 °C. 
Figure 6 - Illustrative demonstration of a secondary peak of S100B 
in a patient suffering from TBI. The delta (difference) from the 
“baseline” is highlighted. Only peaks detected 48 hours after 
trauma were used (dotted line) (Paper II). 
 38 
3.5.1 S100B analyses 
In Paper I, II and IV up until September 2008, a quantitative automated immunoassay was used 
(LIASON, DiaSorin, Italy).  It is a two-site chemiluminescence immunoassay (sandwich principle) 
based on paramagnetic particles coated with two monoclonal antibodies and a monoclonal conjugate 
antibody labelled with an isoluminol derivative. During a first incubation, S-100 present in samples 
binds to the solid phase monoclonal antibodies, and subsequently after a washing step in a second 
incubation the antibody conjugate reacts with S-100 already bound to the solid phase. After 
incubation, the unbound material is removed with a wash cycle. Subsequently, the starter reagents 
(alkaline peroxidase and a catalytic solution, with protohematin) are added and a flash 
chemiluminescence reaction is thus induced. The light signal (425 nm), and hence the amount of 
isoluminol-antibody conjugate, is measured by a photomultiplier as relative light units (RLU) and is 
directly proportional to S-100 concentration present in calibrators, samples or controls. 
In September 2008, an automatic electrochemoluminescence immunoassay assay was introduced 
(Modular E170, Roche Diagnostics, Germany). The assay uses a sandwich complex, comprising of a 
biotinylated monoclonal S100B specific antibody and a monoclonal S100B specific antibody labeled 
with ruthenium. For incubation, streptavidin-coated microparticles were added and attached the 
complex to the solid phase through an interaction between biotin and streptavidin. Magnetic particles 
were captured on the electrode surface, and unbound particles were washed off. An electrode voltage 
was applied which induced the chemiluminiscent reaction detected using a photomultiplier. Some 
samples in Paper I, II and IV, as well as all samples in Paper III, were analyzed using the Roche 
Modular E170.     
A commercially available S100B ELISA kit was used in Paper V (CanAg EIA S100, Fujirebio 
Diagnostics AB, Göteborg, Sweden). The samples where thawed overnight at 4°C and were added 
(50µl per well) to a pre-coated 96 well plate and run in duplicates, according to the protocol. The 
results were analyzed using a Multiskan EX and Ascent Software V2.6 (ThermoLabSystems, Thermo 
Scientific, Waltham, USA). Absorbance was measured at 620 nm and a cubic spline curve fit method 
was used to fit the absorbance as recommended by the manufacturer. Extrapolation was used for 
sample levels outside calibration reference levels. Outliers (deviating more than 3 standard deviations) 
were excluded (n=3) (two normoxic, day 7 and one sham, day 1), as well as animals with an 
inadequate sample volume (n=1) (hypoxic, day 7).  
All methods analyze the BB and AB dimers of S100B, and have been used in several other studies. 
The LIASON assay was developed for diagnosis of malignant melanoma, while the Roche Modular 
E170 is more tailored for TBI and emergency use, hence being faster (36 hours vs 18 minutes). The 
two assays have been shown to yield slightly dissimilar results, with a mean difference of 0.14 µg/L, 
with a variance being higher in more elevated concentrations >0.6µg/L (Alber et al., 2005, Muller et 
al., 2006). A general pattern has emerged, revealing that the Roche Modular E170 presenting 
significantly lower levels. However, the two methods usually show a good correlation, up to r=0.932 
(Smit et al., 2005, Mussack et al., 2006). In order to validate the two assays, the Department of 
Clinical Chemistry, Karolinska University Hospital ran both methods simultaneously for 6 months and 
no clinical significant difference between the two assays could be found, as supported by an internal 
publication of verification (Bergman, 2009).  
3.5.2 NSE analysis 
In Paper III and IV NSE samples were analyzed using the same method as for S100B prior to 
September 2008, a quantitative automated immunoassay (LIASON, DiaSorin, Italy).  It is a two-site 
chemiluminescence immunoassay (sandwich principle). The method is very sensitive to hemolysis, so 
a sample was not analyzed if hemolysis (defined by haptoglobin concentration >0,5 g/L) was present. 
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3.5.3 NFL analysis 
In Paper IV, determination of serum and CSF levels of NFL were analyzed using a commercially 
available ELISA kit (Uman Diagnostics, Umeå, Sweden) in line with the manufacturer’s instructions. 
Measurements were performed in duplicates, using 50 µl undiluted cell-free serum, or 10µl CSF, per 
well. If levels were not within detection limits, that specific samples were re-run at a lower or higher 
dilution. NFL has been shown to be relatively stable, not affected by repetitive thawing (up to 4 thaws) 
(Kuhle et al., 2013).  
3.6 MICRODIALYSIS MONITORING 
In Paper I, II, III and IV intra-parenchymal microdialysis probes (CMA70, 10mm membrane, mDialysis 
AB, Stockholm, Sweden) were inserted when deemed appropriate by the attending neurosurgeon on 
call. In focal injuries, the probe was aimed for the peri-contusional locale (Nelson et al., 2011), while in 
diffuse injuries, the probe was placed in the right frontal lobe, according to international guidelines 
(Bellander et al., 2004b). Following the surgical procedure, the MD-catheter was connected to a MD-
pump device (CMA 106, mDialysis AB, Stockholm, Sweden). A commercially available perfusion fluid 
(“Perfusion Fluid CNS”, mDialysis AB, Stockholm, Sweden), was used as a carrier, pumped at 
0.3µL/min. The MD-pumps acquired samples were stored in microvials (holding 200µL). The 
microvials were analyzed simultaneously every hour with a CMA600 enzyme-photometric analyzer 
(mDialysis AB, Stockholm, Sweden). Glucose, lactate, pyruvate and glycerol where analyzed regularly 
every hour. MD monitoring, as well as all other invasive intracranial monitoring, were withdrawn when 
the patient regained consciousness. While MD monitoring was used sporadically for patients in Paper 
I, II and IV, only Paper III presents analyzed MD data. 
In Paper III, all patients had a CMA70 intra-parenchymal catheter, as previously described, and a 
CMA64 IView catheter (10mm membrane, mDialysis AB, Stockholm, Sweden) inserted in an external 
ventricular drain device. The CMA64 catheter was connected to a CMA106 MD pump, with the same 
perfusion fluid and perfusion velocity as the intra-parenchymal catheter. The CMA64 was placed 
inside a four-way stopcock (Multiflo3, BDConnecta, Franklin Lakes, NJ, USA), connected to both an 
extraventricular drain and a LiquoGuard® (Möller-Medical, Fulda, Germany) CSF-pump set to pump 
CSF with 2 mL/h, hence constantly being located in flowing CSF. The microvials where sampled with 
the same method and frequency as the CMA70 microvials. Data was presented as median and 
interquartile range. 
3.7 NEURORADIOLOGICAL EXAMINATIONS 
In Paper I, the presence of traumatic subarachnoid hemorrhage, subdural hematoma, hypodense 
lesions, epidural hematoma and cerebral contusions, on admission CT scan, were noted. Any midline 
shift was measured in millimeters and reported. Further, potential progression of the intracranial 
hematoma between the first and second CT-scan, was documented (Narayan et al., 2008). 
For Paper II, all specific pathology noted on initial CT-scans included in Paper I were used. Also, all 
subsequent CT and MRI readings where reviewed by a neuroradiologist and if a secondary 
pathological development was detected, it was documented. Infarctions were discriminated from 
edema using either MRI, or subsequent CT-scans to determine if the initial hypodense region had 
diminished, and if so it was defined as edema. 
In Paper III and IV, the admission CT scans were reviewed using different classification protocols, 
including Marshall CT classification (Marshall et al., 1991), Rotterdam CT score (Maas et al., 2005) 
and Stockholm CT score (Nelson et al., 2010).  
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Paper V used an ex-vivo (decapited heads) MRI examination, utilizing a 9.4 Tesla machine with the 
following protocols; T2, fractional anisotropy (FA) and diffusion weighted imaging (DWI). T2 protocols 
were used to determine lesion size using the “free-hand tool” in ImageJ (1.48v, NIH, Bethesda, MD, 
USA) while ADC was measured for cytotoxic and vasogenic edema. It was performed in two rats per 
survival day and normoxia/hypoxia group, including sham. In total n=23 were performed (one hypoxic 
brain day 28 was missing due to procedural errors).  
3.7.1 Computerized Tomography (CT) 
All patients, in Paper I, II, III and IV, had been subjected to a head CT-scan prior to admission either 
at Karolinska University Hospital or at another hospital. By protocol, subsequent neuroradiological 
investigations were often performed following neurosurgical interventions, when patient deterioration 
was present or in absence of clinical improvement.  
3.7.2 Magnetic Resonance Imaging (MRI) 
MRI was often performed within 10 days after injury to detect potential DAI in Paper I, II, III and IV. As 
can be seen in Paper II, it was performed predominantly in the severe TBI patients (79%). The clinical 
course, and structural damage on CT, determined if a MRI was performed. For the human studies, the 
MRI used was a 1.5 Tesla machine using the following protocols; Echo Planar (EP) diffusion, Fluid 
Attenuated Inversion Recovery (FLAIR), Gradient Echo (GRE), T1 and T2. As clinical routine, the 
neuroradiological scans were all reviewed by two specialists in neuroradiology. In Paper IV, a blinded, 
dedicated specialist in neuroradiology reviewed all scans noting the extent of DAI.  
In Paper V, the software ImageJ® (1.48v, NIH, Bethesda, MD, USA) was used to map the lesion area 
using the “Freehand selections”. T2 images from survival times at 7, 14 and 28 days were used since 
they had well-defined lesion areas. The largest lesion area per brain was chosen for quantification. 
Also, in Paper V, the freehand tool in ImageJ was used to detect the pericontusional area with an 
increased diffusion by measuring apparent diffusion coefficient (ADC) signaling indicating vasogenic 
edema and a decreased ADC indicating cytotoxic edema (Unterberg et al., 1997, Maeda et al., 2003, 
Unterberg et al., 2004). All MRI slides including edema were quantified and displayed as max value 
per animal. 
3.8 CLINICAL PARAMETERS AND SECONDARY INSULTS 
Age, sex, pupil responsiveness (graded as 0 = bilateral responsive, 1 = unilateral unresponsive and 2 
= bilateral unresponsive) and Glasgow Coma Scale (Teasdale and Jennett, 1974) were documented 
at admission to the hospital in Paper I, II, III and IV.  
In Paper I, pre-admission hypoxia (oxygen saturation <90% or respiratory obstruction) and 
hypotension (systolic blood pressure <90mmHg), were retrieved from ambulance charts. Multitrauma 
was defined according to Advance Trauma and Life Support (ATLS) guidelines, if thoracic, abdominal 
or skeletal injury were present on initial radiological examinations, or if the cause was a high-energy 
injury trauma (Committee on Trauma, 2008) (also noted in Paper II). 
Paper II included several secondary insults monitored in the NICU, graded according to the Edinburgh 
University Secondary Insult Grade (EUSIG) (Jones et al., 1994). ICU-Pilot® (mDialysis AB, 
Stockholm, Sweden) was used to monitor patients in the NICU, and record secondary insults. The 
peak level of ICP during the treatment period, exceeding 5 minutes, was noted and divided into 4 
groups; <20 mmHg (no secondary insult), 20-29 mmHg (mild secondary insult), 30-39 mmHg 
(moderate secondary insult) or ≥40 mmHg (severe secondary insult). Also, during 1.5 days prior to a 
secondary peak of S100B and 1.5 days after, secondary insults were extracted from the monitoring 
data. The secondary insults were present for >5 minutes, in order to be recorded. Presence of 
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increased ICP (>20 mmHg) was noted. The total burden of secondary insults were also recorded, 
including increased ICP (>20 mmHg), low cerebral perfusion pressure (CPP, <50mmHg), 
hypertension (systolic blood pressure >160mmHg, mean arterial pressure >110mmHg), hypotension 
(systolic blood pressure <90mmHg, mean arterial pressure <70mmHg) and pyrexia (>38°C) prior to, 
and after the secondary peaks of S100B. The lowest concentration of hemoglobin was also noted, as 
it was thought to possibly affect the development of secondary ischemic lesions. 
Additionally, Paper III noted Abbreviated Injury Scale Score (AIS) and Injury Severity Score (ISS) at 
the admission to the NICU. Conventional CSF parameters (glucose, lactate, erythrocytes, leukocytes, 
and albumin) were acquired as they were sampled in the NICU. 
In Paper V, per-operative data (pulse, saturation, perfusion) as well as post-operative blood gas 
samples (pO2, pCO2, pH, Lactate, Glucose, Hb, Na, K) were acquired. Data were displayed as median 
and interquartile range.   
3.9 IMMUNOHISTOCHEMISTRY   
3.9.1 Sample preparation 
In Paper V, following euthanasia, the brain was formaldehyde perfused, and transferred to PBS 
solution in +4°C, waiting sectioning. Later on, the brain were moved to a 30% sucrose solution for 
three days and where then immediately frozen to -80°C. The brains were then sectioned in coronal in 
14 µm thick sections. The sections where frozen in -10°C. 
3.9.2 Antibodies used in immunohistochemistry 
In Paper V, commercially available 
primary and secondary antibodies were 
used. For information concerning 
secondary antibodies, please see 
Paper V. To best visualize the immune 
cell activation to cerebral injury, we 
used CD68/ED1 to detect 
macrophages (and activated microglia) 
and CD43/W3/13 for granulocytes. 
NeuN was used to detect viable 
neurons and measure the lesion size. 
For detection of the end stage of the 
complement cascade, we used a 
specific antibody against the 
membrane attack complex (C5b9). Due 
to the lack of signal using the C5b9 immmunofluorescence, an alternative tyramide signal 
amplification (TSA) procedure was employed. Also, expression of HIF-1α was included to monitor its 
changes following hypoxia/normoxia while vascular endothelial growth factor (VEGF) was used to 
detect an increased angiogenesis signaling and IgG extravasation to quantify the extent of BBB 
disintegration. DAPI was chosen as cellular counterstain. As control, all secondary antibodies were 
tested with omission of the primary antibodies resulting in no significant background noise. Sham 
surgery animals were also used (n=2 from normoxia and hypoxia, day 1). 
3.9.3 Immunohistochemistry protocol  
A standard staining protocol was used to primary, and secondary, incubate the sections of 
formaldehyde perfused, frozen brain tissue (see Paper V for a more detailed description). The primary 
antibodies were diluted in 0.3% TX-100 (X100, Sigma-Aldrich, St.Louis, USA) + 0.1% NaN3 in PBS 
Figure  7 – NeuN (white) expression on a coronal section following cortical 
controlled impact. The missing cortical area is quantified. 
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pH7.4 for 16 hours (4°C) while the secondary antibodies were mixed in a Tris-NaCl-blocking buffer 
(TNB-buffer, FP1020, PerkinElmer, Waltham, USA), incubating in the dark for 90 minutes in room 
temperature. Sudan black was used to minimize background fluorescence. Sections were mounted 
using PVA/DABCO (ProLong® Gold antifade with DAPI, P36931, Life Technologies, Thermo Fisher 
Scientific, Waltham, USA) and stored in -20°C before being scanned. For more information 
concerning which primary and secondary antibodies that were used, see Paper V. 
3.9.4 Microscope 
In Paper V, a scanning microscope (MetaSystems, Alltlussheim, Germany), using a 10x objective and 
different filter sets where used. Whole microscope slides were pre-scanned scanned at 2.5x to 
generate a tissue-map. All tissue-covered areas were scanned using 10x primary objective. Individual 
images were stitched together (VSlide) to generate a large fluorescence image of the entire slide. 
3.9.5 Image analysis 
In Paper V, to quantify neuronal survival, the software ImageJ was used to map the cortical layer 
where NeuN expression was absent, using the “Freehand selections” (Figure 7). All brains where 
used and at least three sections per brain were quantified. The larger area of neuronal loss in the 
cortical layer was chosen for further analyzes. The NeuN area revealed a more consistent result than 
the DAPI area since DAPI is more sensitive to debris in the lesion cavity and to the quality of the 
section (if the tissue is folded, slightly out of focus etc.). 
ImageJ was also used to analyze all other antibody expression in the cortical tissue surrounding the 
lesion (upper right corner). A cut-off threshold was chosen for each antibody. The threshold varied 
depending on the fluorescence intensity of each antibody in order to eliminate potential background 
expression. The staining was automatically quantified using macros created in ImageJ similar to 
methods described previously (Papadopulos et al., 2007, Gandhi et al., 2012). All available slides 
were used, with a minimum of three sections per brain for each antibody. The slide with the highest 
staining intensity per brain was selected and expressed as “Integrated density”, including all pixels 
above the specified cut-off. One rat (ET012, hypoxia 7 days) presented as an outlier for all antibodies 
used in the immunofluorescence experiments and was thus excluded from the study. 
3.10 STATISTICAL ANALYSIS 
The statistical program R (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-
project.org) was used throughout all Papers. To plot the line graphs in Paper III, GraphPad Prism 6.0 
(GraphPad Software Inc., 2014) was used. In Paper I, II and IV, GCS was used as continuous 
variable, as has been done previously (Perel et al., 2008). Throughout all Papers, a p-value <0.05 
was considered statistically significant; however a Bonferroni correction was applied in Paper III due 
to a low sample size. For more detailed analyses, see the specific papers.  
3.10.1.1 Paper I 
A prediction model was used, using admission parameters known to influence outcome, where S100B 
was added to establish to which extent the estimated explained variance was increased, using the 
“rms”-package in R. Accuracy of all models was evaluated using Nagelkerke’s pseudo-R
2
, which 
provides a partial prediction between 0 and 1, where 1 is a fully explained model (also used in Paper 
II, III, IV and V). Multivariate analyses, with a stepwise reduction based on Akaike Information 
Criterion, were performed with imputed data to determine which variables had an independent 
correlation to outcome. Additionally, a linear regression was performed to determine what parameters 
were correlated to levels of S100B. The temporal relation between sample-time, and the strength of 
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correlation between S100B and outcome, was investigated using a sliding time window of 100 
samples examined using a proportional odds model of GOS prediction.  
3.10.1.2 Paper II 
Logistical regression was performed, to determine parameters correlated to the development of 
secondary radiological findings, and proportional odds analyses were performed to analyze 
parameters correlated to patient outcome. The “rms”-package in R, and Nagelkerke’s pseudo-R
2
, was 
used in univariate analyses. Multivariate analysis, using a step-wise reduction of parameters, was 
performed to determine which parameters were independently correlated to the development of 
secondary radiological pathology, and to patient outcome. Sensitivity, specificity, negative predictive 
value and positive predictive value for the different cut-off levels, of secondary peaks of S100B, were 
calculated. A receiver operating characteristic curve (ROC curve) was provided as to best determine 
which cut-off level to use. A Wilcoxon Rank-Sum test was performed to determine any significant 
difference between secondary insults (ICP and total secondary insult burden), prior to and after, the 
secondary increase of S100B. 
3.10.1.3 Paper III 
The “rms”-package in R was used to perform univariate logistic regression analyses, examining the 
correlations between levels of conventional CSF- and MD-CSF glucose and lactate, as well as for 
outcome predictions. Bland-Altman plots were used to illustrate similarity between conventional CSF-
samples and MD-CSF samples (Bland and Altman, 1986). A Mann-Whitney-U Test was used to 
assess association between median MD parameters (in brain and CSF) and favorable- and 
unfavorable outcome.  
3.10.1.4 Paper IV 
The “rms” package for proportional odds models was used. Parameters known to be predictive of TBI 
outcome were included (Age, GCS, Pupil response, CT score, and trauma grade (ISS, AISS)) as 
adjusting parameters. Since data on NFL was sampled 1-3 times per patient and at different time 
points, mixed model analyses were not possible. As an alternative median, mean and max values 
were determined and used in the statistical models. To near a normal distribution, logarithm values for 
NFL, S100B and NSE data were used. Multivariate proportional odds analyses were performed 
towards GOS. The explained variance of linear models when identifying parameters related to serum 
and CSF NFL is given as an adjusted R
2
. A Mann-Whitney U-Test was used to compare NFL levels in 
patients with and without DAI in Marshall Grade II patients. 
3.10.1.5 Paper V 
To correlate intra-operative monitored data and post-surgery metabolic data, Mann-Whitney U Tests 
were employed to allow comparisons between normoxic and hypoxic animals. The MRI lesion size 
was illustrated by using bar plots and compared using a Mann-Whitney U Test. Linear regression 
analyses were performed to correlate antibody expression, as well as S100B levels and edema, to 
hypoxic/normoxic group and to time after injury. A Student-T-Test was performed on S100B levels the 
first day to compare hypoxic and normoxic animals.   
3.10.2 Missing Data 
In Paper I, II and IV missing data was imputated using multiple imputations (MI). This was done by 
using the “MICE” package in R. Seven imputations have been suggested by the International Mission 
for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) investigators, in order to further improve 
the quality of retrospective analyses (McHugh et al., 2007a). MI exchanges missing values by an 
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estimate drawn from a distribution of known data, retaining the uncertainty of the imputed data in 
following analyses.   
In Paper III and V, missing data were excluded from the analyses.  
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4 RESULTS 
4.1 BIOMARKERS IN RELATION TO OUTCOME CORRELATION 
Paper I showed that later S100B levels 
sampled later resulted in higher predictive 
capabilities toward long-term outcome than 
the initial samples. The peak and area under 
curve (AUC) levels of S100B both had a 
higher pseudo-R
2
 in explaining outcome 
prediction than age, pupil responsiveness 
and GCS at admission (Table 5). In 
multivariate analysis, age, pupil 
responsiveness and S100B levels (log AUC) 
correlated independently to GOS. 
Unexpectedly, GCS was not independently 
correlated to outcome. Using a core model of 
CT-findings, age, pupil responsiveness and 
GCS, S100B provided an additional 
explained variance of 6.6%, yielding a total 
of 35.8%. In Paper IV, we found that, in 
addition to serum levels of S100B, serum 
levels of NFL provided a significantly 
(p=0.006) increased estimated partial 
pseudo-R
2
 of 2.3% towards functional 
outcome prediction if used together with 
other core parameters (Stockholm CT score, 
pupil responsiveness, age, S100B and GCS 
at admission).   
Also, Paper I revealed a discrepancy 
between AUC and peak levels in some 
patients, especially if the peak of S100B 
occurred early (within 12 hours) after trauma (Figure 9). It was concluded that S100B should be 
sampled 12-36 hours after injury in order to better improve outcome predictions, where it may reach a 
pseudo-R
2 
of 0.20-0.25% towards long-term outcome prediction. 
Paper II showed that the development of secondary pathological findings on CT/MRI was 
independently correlated to outcome. In univariate ordinal regression analysis, a secondary injury 
development and a secondary peak of S100B were highly correlated to outcome (pseudo-R
2 
= 0.111 
and 0.100, respectively), only exceeded by age (pseudo-R
2 
= 0.122). A multivariate analysis revealed 
that, both secondary peaks of S100B and subsequent radiological findings are both independently 
correlated to long-term outcome, however they present significant co-linearity, thus not being 
independently correlated if they are present together in prediction models. Using secondary injury 
development on CT/MRI, an additional 1.3% is added of explained variance to predict long term 
outcome.  
Factor p-value pseudo R
2
 
log S100B AUC first 48 hours <0.0001 0.119 
log S100B Peak level first 48h <0.0001 0.109 
Age <0.0001 0.102 
Pupil responsiveness <0.0001 0.079 
EDH on CT scan 0.0008 0.044 
Progression of intracranial 
hematoma on CT scan 
0.0012 0.037 
Hypodense lesion on CT scan 0.0016 0.039 
GCS at admission 0.0062 0.023 
SDH on CT scan 0.0126 0.021 
Midline shift on CT scan 0.0305 0.017 
Hypotension at SoA 0.0532 NS 
trSAH on CT scan 0.055 NS 
Contusion on CT scan 0.087 NS 
Gender 0.427 NS 
Multitrauma 0.525 NS 
Hypoxia at SoA 0.880 NS 
Table 5 - Ordinal regression analyses of parameters and their 
correlation to outcome (GOS 1–5) 
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Paper III showed that increased levels 
of lactate and pyruvate, extracted 
using MD-CSF, were correlated to an 
unfavorable outcome (GOSe 1-5 vs 6-
8) (p=0.0167 and p=0.0293, 
respectively) (Figure 8). Using 
conventional (regional) microdialysis 
analyzing ECF samples, no significant 
correlation could be found. 
4.2 BIOMARKERS IN 
RELATION TO MONITORING 
In Paper II, we detected secondary 
CT/MRI pathology, not present at 
admission, in 39% TBI of cases, 
predominantly cerebral infarctions or 
other ischemic injuries. These 
secondary radiological events occurred 
in proximity to secondary increases of 
S100B. A secondary increase of 0.05 
µg/L of S100B resulted in a pseudo-R
2
 
of 0.532 in correlation to the 
development of secondary radiological 
findings. Other cut-offs of secondary S100B were used, including 0.10µg/L and 0.5/L, which also 
yielded significant results. Moreover, in a multivariate model, low admission GCS, hypodense lesions 
on CT-scans and an increased ICP (present sometime during the NICU stay) also independently 
correlated to the development of subsequent radiological pathology. In total, a pseudo-R
2
 of 0.704 
towards predicting these secondary findings was found using a core-model of secondary peaks of 
S100B, age, pupil and GCS-, hemoglobin-, ICP- and admission CT-parameters. Using a lower 
(0.05µg/L) cut off compared to 0.1µg/L, or 0.5, µg/L, there is an increase of sensitivity (0.5=16% - 
0.1=62% - 0.05=80%) 
with only a limited loss 
of specificity (0.5=98% - 
0.1=95% - 0.05=89%), 
to detect secondary 
radiological findings. A 
receiver operating 
characteristic (ROC) 
curve yielded an AUC of 
0.855 using secondary 
peaks of S100B to 
detect subsequent 
radiological pathology 
(Figure 10). 
In an attempt to predict the secondary increases of S100B with conventional monitoring and 
subsequent deterioration in the NICU, increased ICP alone, and increased ICP together with 
decreased CPP, hypertension, hypotension and pyrexia were monitored 36 hours prior to and after 
the secondary peak of S100B but no significant difference could be detected.  
Figure  9 -  Precision of S100B  to predict outcome in relation to time from 
injury. The x-axis indicates when S100B was sampled in relation to the time 
of trauma (hours). The y-axis represents the pseudo R
2
 of a proportional 
odds model predicting outcome as Glasgow Outcome Score (GOS). The 
smooth line represents a locally weighted scatterplot smoothing (LOWESS), 
a regression of data points.  
Figure 8 - Median MD-CSF lactate and MD-CSF pyruvate levels versus outcome (GOSe 1-5 
vs 6-8). MD-CSF lactate levels and MD-CSF pyruvate levels are significantly higher in patients 
with an unfavorable outcome (p=0.0167 and p=0.0293 respectively).  
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In Paper III, a new method of monitoring cerebral 
metabolism using MD catheters in flowing CSF 
was used. The method revealed a good 
concordance between conventionally sampled 
glucose and lactate levels from the CSF. 
According to us, a clinically accepted variance of 
0.51 and 0.13 was detected (Figure 11). The MD-
CSF samples were not significantly influenced by 
CSF erythrocyte-, leukocyte- or albumin 
concentrations. Using the MD-CSF, metabolites in 
CSF could be detected with a better temporal 
resolution than has been previously described. 
This new monitoring technique detected higher 
levels of glucose in CSF while lactate, pyruvate, 
LPR and glycerol were higher in ECF, 
independent of pericontusional or non- 
pericontusional location. 
Paper IV showed that NFL levels in serum 
following TBI remain relatively unchanged over 
time in the individual patient, even if there are concentration differences between patients (Figure 12).   
In Paper V, per-operative monitoring and post-surgery metabolic data confirmed a hypoxic status. 
Hypoxic animals had significantly higher pulse and lower peripheral perfusion than normoxic animals 
(p=0.0314 and p<0.0001, respectively). The hypoxic animals had, apart from lower pO2 
concentrations, significantly higher lactate, glucose and pCO2 concentrations following 30 minutes of 
hypoxia.  
4.3 BIOMARKERS IN 
RELATION TO 
STRUCTURAL 
DAMAGE 
In Paper I, a univariate 
analysis was performed to 
determine which factors that 
correlated with serum 
concentrations of S100B. 
The step-wise reduction 
model retained only CT 
parameters, including 
traumatic subarachnoid 
hemorrhage, absence of 
epidural hematoma, 
contusions, midline shift, 
hypodense lesions and progression of intracranial hematomas as significantly correlated to S100B 
levels. Noteworthy was that a progression of intracranial hematomas was seen in 59% - 61% of the 
patients (Paper I and Paper II, respectively). Interestingly, multitrauma did not correlate significantly to 
S100B levels.  
Figure  10 - ROC curve of secondary peak of S100B cut-off 
levels and the predictability to detect a subsequent 
pathology on CT or MRI.  
Figure 11 - Bland-Altman plots of the CSF glucose and CSF lactate samples (n=29) 
corresponding with MD-CSF glucose (left) and MD-CSF lactate (right). The points are 
plotted with the difference between two observations (pair-wise difference) on the y-axis, 
and the mean of the two observations (mean-wise difference) on the x-axis. The 
confidence limits and the mean are plotted as black lines. The variance for glucose and 
lactate are 0.51 and 0.13 respectively. Every patient (n=14) is represented by a unique 
color. Two points lay outside the confidence limits for glucose while one point is outside 
the confidence limits for lactate. 
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Serum NFL levels were not significantly 
correlated to diffuse axonal injury as noted on 
MRI scans, or to damage assessed using CT 
scoring protocols, as was shown by Paper IV. 
Levels of NFL were significantly correlated to 
levels of NSE, but not to S100B. 
Using ex-vivo MRT in Paper V, a significantly 
larger lesion size was detected in the hypoxic 
animals at day 7, 14 and 28 compared to the 
normoxic animals (p=0.017) (Figure 13). 
Neuronal survival, as defined by NeuN 
expression, was also significantly increased in 
the normoxic animals (p=0.032). 
In Paper V, surprisingly, HIF-1α and VEGF 
expression were higher in normoxic animals 
compared to hypoxic animals (p=0.042 and 
p=0.038, respectively). HIF-1α decreased 
significantly over time while VEGF expression 
remained unchanged.  
In Paper V, based on MRI analysis, we noted that cytotoxic edema increased rapidly after TBI and 
then gradually decreased over time (p<0.0001). However, the area of vasogenic edema had a lesser 
pronounced temporal pattern. When comparing both treatment groups, we found no differences in the 
extent of brain edema between hypoxic and normoxic animals. C5b9 was upregulated in the peri-
lesional area, primarily expressed in surrounding neurons. The highest expression was seen 
immediately after trauma and then steadily decreased over time but no significant differences were 
seen between 
oxygenation groups.  
ED1 expression in 
Paper V was 
predominantly seen in 
the peri-lesional 
subcortical white matter, 
although also spread 
out over the cortical 
areas while CD43 
(granulocyte) 
expression was only 
detected in the peri-
lesional area. ED1 
expression revealed a 
temporal pattern, 
increasing significantly 
over time whereas 
CD43 remained 
unchanged. 
Interestingly, there was a correlation between the amount of macrophage infiltration and the area of 
vasogenic edema (p=0.011, r
2
=0.381). IgG extravasation, as an indicator of BBB disruption, was 
expressed in the perilesional zone and peaked early after injury and then steadily decreased without 
Figure 13 - A displays the difference between lesion size for normoxic- (n=6) and hypoxic 
rats(n=5) during survival times d7, d14 and d28. In B, the lesion size on two d28 animals are 
visualized; normoxia 28 days following TBI (left) and hypoxia 28 days following TBI (right). C 
illustrates how the lesion size on MRI increased over time in hypoxic (red) and normoxic (blue) 
(R
2
=0.721). The gray area represents 95% confidence interval while the line is a regression 
line. D correlates lesion size using missing NeuN area and lactate levels acquired from blood 
gas post-surgery; as lactate increases, so does the lesion size (R
2
=0.318). 
Figure 12 - Serum NFL levels for all patients (Paper IV). Every line 
(separate color) represents an individual patient. Generally, even if 
there were differences in concentration between patients they were 
limited over time for the individual patient. 
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any significant difference between hypoxic and normoxic animals. Notably, IgG extravasation was 
highly correlated to C5b9 expression (p<0.0001, r
2
=0.759).  
Further, in Paper V, S100B levels in serum 24 hours after inflicted injury revealed a trend towards 
being higher in hypoxic compared to normoxic animals (p=0.0844).  
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5 GENERAL DISCUSSION 
5.1 BIOMARKERS IN RELATION TO OUTCOME CORRELATION 
In this thesis, we present two of the largest studies to date of TBI patients in neuro-intensive care 
monitored using serum levels of the biomarker S100B (Paper I and II). While several studies have 
shown a correlation between levels of S100B and outcome, Paper I analyzed more frequent S100B 
sampling in multivariate models towards outcome. Our data indicates that serum levels of S100B have 
a robust correlation to clinical outcome, adding 6.6% in addition to core parameters (CT findings, age, 
GCS at admission and pupil responsiveness), which is difficult to compare with other studies but is 
probably on par or better than parameters such as age, pupil responsiveness and age (Murray et al., 
2007). Furthermore, in a univariate analysis, we found S100B to better than age, GCS and pupil 
responsiveness explain long-term outcome. This could partly be explained by the timing of 
assessments, since GCS and pupil responsiveness were examined at admission to the hospital and 
not like S100B which was sampled up to 48 hours after injury. Low GCS two days after injury would 
probably have had a greater explained variance towards outcome than on admission, which has been 
previously shown (Lee et al., 2012). However, it is not always possible and could be harmful to wake a 
sedated patient with a possible intracranial hypertension in the first days following trauma for 
adequately assess the GCS (Skoglund et al., 2009, Helbok et al., 2012). Moreover, pupil 
responsiveness is useful in the emergency setting in order to detect intracranial mass lesions, but 
following hematoma evacuation it may not be as accurately correlated to long-term outcome. In 
conclusion, future outcome prediction models of TBI will improve their predictive capabilities should 
S100B levels be incorporated (Lesko et al., 2014), in addition to other core parameters.     
Unexpectedly, GCS in our material (in Paper I, II and IV) was found not be a strong predictor towards 
long-term outcome (pseudo-R
2
 of 2.3%, 1.8% and 1.6% (p>0.05) respectively in each paper). The 
hospital admission GCS, usually the golden standard, was used in our study, which sometimes is 
affected by sedative medications (Balestreri et al., 2004) and may thus be inferior to other assessed 
intervals, such as the post-resuscitation GCS or GCS assessed at the scene of accident. GCS is also 
complicated to assess due to multitrauma, speech impediments, eye injury and has been seen to 
present a high intra-personnel variance (Bledsoe et al., 2014). Also, by using only the motor 
component in GCS, a better prediction to long-term outcome has been seen compared to the other 
components (Healey et al., 2003). In aggregate, we believe that if the GCS score was assessed at 
another time interval, or if the three different GCS components had been available for analysis, 
perhaps it would better reflect the severity of the intracranial injury and thus improve outcome 
prediction in TBI patients. 
In Paper IV, we found that by adding serum levels of NFL to an outcome prediction model including 
S100B (and CT-findings, age, GCS and pupil responsiveness), additional significant explained 
variance was found (2.3%), presumably indicating that another clinically important pathophysiological 
processes was monitored by analyzing serum levels of NFL in addition to S100B. Other biomarker 
combinations have shown to increase outcome prediction, including GFAP+S100B (Vos et al., 2010), 
NSE+S100B+GFAP (Vos et al., 2004) and UCHL-1+GFAP (Mondello et al., 2012), presumably as 
surrogate markers for different cellular damages. However, also in Paper IV, CSF levels of NFL failed 
to show any significant correlation to long-term outcome, an analysis that perhaps was relatively 
underpowered due to a lower sample size. Altogether, we believe that a panel of biomarkers should 
be used to monitor different clinically important pathophysiological intracranial processes following 
TBI.    
In Paper I, a discrepancy between early peak levels and AUC levels of S100B was detected. This 
phenomenon has been previously described for very early samples of S100B, which will quickly 
decrease within the first hours (Jackson et al., 2000). It is postulated that these quick falls could be 
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due to decreased permeability of the BBB, which has been shown in experimental TBI to only be open 
30 minutes after injury (Barzo et al., 1997a). Although more novel research has suggested that the 
glympahtic systems drains S100B from the brain to serum, independent of BBB integrity (Plog et al., 
2015), and this would release high levels of S100B into serum from CSF and the damaged brain. 
Either way, systemic S100B levels would decrease swiftly as the in-vivo half-life has been shown to be 
as short as 20 minutes (Jonsson et al., 2000). Another reason why S100B increases shortly after 
injury could be a contribution of S100B from extracranial injury, bone/adipose/muscle tissue in 
multitrauma patients (Pelinka et al., 2003), but has been shown to have a very limited contribution for 
the total concentration over time (Pham et al., 2010). After 12 hours, we saw that the predictive ability 
of S100B levels increased dramatically, which is in concordance with other studies that indicate better 
correlation from later sampling. Altogether, timing of S100B sampling is very important since early 
high levels seem to less accurately predict long-term outcome perhaps due extracranial sources of 
S100B.  
The development of secondary cerebral injuries visible on MRI and CT scans was significantly, and 
independently, correlated to long-term functional outcome in Paper II. This finding emphasizes the 
need for advanced neuro-intensive care after the first days following injury in order to detect and 
potentially treat or minimize the extent of secondary injuries.  
Increased CSF lactate and pyruvate levels were seen to correlate to long-term functional outcome in 
Paper III. Isolated increase in lactate levels have previously been described as a predictor of 
unfavorable outcome in TBI patients, perhaps as a marker of hypoxic anaerobic metabolism or 
impaired acid-base status of cerebral cells (Crockard and Taylor, 1972, DeSalles et al., 1986). 
Increased pyruvate levels, together with increased lactate levels, have previously been seen in TBI 
(Toczylowska et al., 2006). It has been postulated that this metabolic pattern could be due to be an 
effect of red blood cell glycolysis in the CSF, or glycolysis in the ischemic affected brain tissue to 
exceeding the ability to adequately metabolize pyruvate, thus leading to increased levels of both 
lactate in pyruvate (Hlatky et al., 2004). Also, cerebral hypermetabolism could lead to similar 
metabolic changes (Foley et al., 2008). However, the erythrocyte levels in CSF were strongly 
correlated to the lactate concentration thus probably indicating a contribution of lactate from red blood 
cells. Altogether, the metabolic pattern of increased lactate and pyruvate levels in CSF seen in Paper 
III are probably the result of high levels of erythrocytes in the CSF, yet other detrimental metabolic 
causes in the affected brain cannot be excluded.   
5.2 BIOMARKERS IN RELATION TO MONITORING 
In Paper II, we detected secondary injuries by radiological tests, predominantly ischemic, in 39% of 
the patients. These findings are greater than previously reported (10-22%) (Mirvis et al., 1990, Raabe 
et al., 2004, Marino et al., 2006, Tawil et al., 2008, Tian et al., 2008, Chen et al., 2013), which could be 
explained by a more liberal use of MRI detecting ischemic injuries not visible on CT scans. 
Our choice of a low cut-off limit (0.05 µg/L) for a secondary peak of S100B greatly increased the 
sensitivity to detect secondary lesions present on CT/MRI scans (n=73 (true positive), a sensitivity of 
80%). If the higher cut-off limit described by Raabe et al. (0.5µg/L) would have been used (Raabe et 
al., 2004), a lot of secondary lesion would have been missed (n=81, a sensitivity of 16%). However, 
these steeper increases of S100B are perhaps more clinically relevant and should thus prompt a more 
rapid diagnostic/therapeutic response i.e. invasive vasospasm treatment, evacuating of mass lesion 
and aggressive ICP management. Transporting ICU patients to perform a radiological examination, or 
for other logistic purposes, are correlated to an increased risk of secondary insults (Andrews et al., 
1990), hence should be done only when they are absolutely necessary, a decision making that 
perhaps could be facilitated by the use of S100B. In a study from Undén et al., they did not see any 
significant correlation of an increase of S100B prior to the development of a secondary neurological 
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deterioration (Unden et al., 2007). In our study (Paper II), it’s impossible to say if imminent treatment 
would have avert the secondary injury that occurred in conjunction with the secondary S100B peak, it 
is however probable that a swift response would, if not prevent, limit the extent of the secondary injury. 
Our twice-per-day sampling of S100B is the most frequent that has been described but presumably, 
several more peaks occurred during the treatment periods since the in-vivo half-life of S100B has 
been shown to be as low as 25 minutes (Jonsson et al., 2000). Moreover, several lesion 
developments probably occurred during the first 48 hours and were perhaps concealed by the primary 
peak of S100B, and could thus not be detected using the current method. In aggregate, repeated 
sampling of S100B revealed secondary peaks which correlated to subsequent injury development and 
should thus be implemented in the multi-modal monitoring of patients suffering from TBI.    
While increased ICP throughout the whole treatment period was correlated to the development of a 
secondary injury on MRI/CT, the ICP (and other secondary insults) 36h before versus 36h after 
secondary peak of S100B did not show any significant difference. Our choice of comparing insults to 
the timing of secondary peak S100B, instead of when the secondary injury was shown on CT/MRI, 
was based on the temporal resolution (CT could be up to several days after the peak while 100B was 
acquired every 12 hours). While some studies have shown that increased S100B levels precedes an 
increase in ICP, they use different definitions of secondary insults, persisting for different amount of 
time and are correlated to different increases of S100B, making comparisons between models difficult 
(Raabe et al., 1999, Olivecrona et al., 2009, Bellander et al., 2011, Olivecrona et al., 2014). However, 
as increased ICP occurring sometime during the NICU treatment correlated to secondary injury 
development, we do believe that intracranial hypertension should be treated and prevented, but that 
the exact timing of subsequent deterioration of intracranial pathology is better assessed if S100B is 
used in addition to conventional multi-modal monitoring. 
In Paper III, we developed a new way of “global” cerebral metabolic monitoring by using a MD 
catheter located in a steady flow of CSF. We found that the recovery of the catheter was higher (98%) 
than from ECF (65%) (Hutchinson et al., 2000) and blood (80%) (Rooyackers et al., 2010), and similar 
to what is found when the MD is located in reference solutions (>90%) (Afinowi et al., 2009). Recovery 
for lactate revealed a lower variance than for glucose, which could be a result due to the small sample 
size but a similar pattern with a strict metabolic control between cerebral compartments have 
previously been described (Guerra-Romero et al., 1992). Presumably, the medium analyzed greatly 
affects the recovery of the MD catheter, increasing in a more water-like solution.  
When monitoring metabolic parameters in CSF and ECF with high temporal resolution (Paper III), we 
noted that glucose levels remained higher in the CSF while lactate, pyruvate and glycerol showed 
higher levels in the ECF. This is probably the result of higher metabolic activity with ongoing cellular 
stress in the ECF of the injured cerebral tissue, compared to the CSF which is an ultra-filtration of 
blood and where the different metabolites will become more diluted, or added from the blood 
(glucose). Anyhow, this further reveals a potential benefit of monitoring both compartments as they tell 
different stories. Furthermore, with the discovery of the glymphatic system and thus newly suggested 
movements between different cerebral compartments, MD will become an even more important 
clinical tool to validate novel findings (Iliff et al., 2012).   
In Paper IV, the intra-individual levels of NFL only generally had limited changes during the first two 
weeks after trauma. This could be the effect of logarithmic data, but could also be explained by the 
long in vivo half-life of NFL which has been shown to be about three weeks (Barry et al., 2007), thus 
considerably longer than the 20 hours for NSE (Ingebrigtsen and Romner, 2002) and 25 minutes for 
S100B (Jonsson et al., 2000). If NFL levels were to be elevated initially after trauma, they will probably 
remain high throughout the first two weeks after TBI, since they will be heavily influenced by the 
primary injury and early pathophysiological cascades. S100B has been shown to have a more 
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dynamic range in its temporal profile and thus perhaps works better as a monitoring biomarker to 
detect secondary injuries in the neuro-intensive care unit (as seen in Paper II). 
In Paper V, we found that the lactate and glucose blood gas levels were increased following 30 
minutes of hypoxia, presumable as a response to the anaerobic environment and a subsequent 
metabolic distress and catecholamine surge in these animals, which has been shown to affect 
outcome in humans (Woolf et al., 1987). This is further supported by pO2 levels that were lower in the 
hypoxic group. Paradoxically, pH was higher in the hypoxic animals than in the normoxic animals, 
even though lactate was increased creating a presumably acidic environment. Perhaps a 
compensatory mechanism, with spontaneous hyperventilation and a secondary respiratory alkalosis 
occurred, as supported by lower levels of pCO2.   
5.3 BIOMARKERS IN RELATION TO STRUCTURAL DAMAGE 
In an attempt to detect which parameters that could explain the levels of S100B in serum, only 
intracranial parameters remained significant in uni- and multivariate analysis. Progression of 
intracranial hematoma was the parameter with the greatest pseudo-R
2
 in univariate analysis (11.6%), 
indicating an ongoing cerebral deterioration in these patients with subsequent high levels of S100B. 
That only intracranial CT parameters were significantly correlated to levels of S100B in serum also 
demonstrates the biomarker’s higher cerebral specificity, compared to potential S100B originating 
from extracranial sources (Paper I). Extracranial sources of S100B have been shown to yield 
increased S100B levels for a limited amount of time (Pelinka et al., 2003) and lower increases than 
intracranial trauma (Savola et al., 2004), perhaps explaining our results that are sampled relatively late 
(up to 48 hours) after trauma. 
In Paper V, we noted that cortical neuronal loss was more pronounced in hypoxic vs normoxic rats, 
which is supported by results from previous investigators (Clark et al., 1997a). As time after injury 
passed, so did the neuronal loss, supported by studies that reveal ongoing apoptosis in the cortical 
region up to a week following hypoxic-TBI (Clark et al., 1997a, Hallam et al., 2004). Blood lactate 
levels, as a surrogate marker of hypoxia, were also significantly correlated to a diminished neuronal 
survival. Lactate levels and survival time (days after trauma), if used together in linear models, 
provided an explanatory pseudo-R
2
 as high as 47% to cortical neuronal death. In summary, we 
demonstrated that hypoxia following focal TBI has detrimental effects on neuronal survival, being 
directly correlated to enhanced levels of lactate immediately after injury. 
Serum concentrations of S100B in Paper V were higher in hypoxic rats 24 hours after impact, though 
not reaching statistical significance (p=0.0868), presumably due to low sample sizes. For the later 
survival times, no difference between the oxygenation groups was observed which is probably the 
result of the limited half-life of S100B which is as short as 25 minutes in humans (Jonsson et al., 
2000). Moreover, protein turnover in rats have been shown to be 10x that in humans, and 28 rat days 
would theoretically correspond to about 5 years in humans, presumably making it difficult to compare 
to human conditions (Quinn, 2005, Sengupta, 2013, Agoston, 2015). In patients we have seen in 
Paper I and Paper II that S100B correlates to the extent of hypodense lesions at hospital admission 
as well as subsequent ischemic development, indicating that if aggravated ischemia is added to the 
brain injury it would lead to an additional increase of S100B. This is further supported by studies on 
perinatal asphyxia and S100B where it has been shown to correlate to the degree of ischemic injury 
(Beharier et al., 2012) as well as in human TBI studies where hypoxia correlated to increased levels of 
S100B (Yan et al., 2014). Altogether, this supports the validity of S100B measured early after trauma 
as a potential biomarker to monitoring severe hypoxic injuries following TBI, albeit further 
investigations including earlier survival times are warranted to verify this assumption.  
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In Paper V, we saw that hypoxia increased the lesion size by using ex-vivo MRI examinations, making 
this the first to our knowledge to analyze lesion size using MRI over an extended time period. 
Previously, focal hypoxic-TBI models have revealed an increase in cortical lesion size by using 
immunohistochemical techniques (Bramlett et al., 1999b, Matsushita et al., 2001). Only 7, 14 and 28 
day examinations were chosen since they had well defined lesion cavities. The extent of vasogenic 
and cytotoxic edema was not significantly different between the hypoxic or normoxic groups, as is 
supported by a similar study by a collaborating group that also failed to detect any significant increase 
of brain edema during hypoxic conditions (Yan et al., 2011), although different models were used. 
Previous studies that do detect increased edema in hypoxic vs normoxic TBI all use fluid percussion 
models (Ishige et al., 1987, Van Putten et al., 2005, Gabrielian et al., 2011) which perhaps provides a 
more well defined affected area not influenced by the lesion cavity that might be more suitable for 
edema formation and quantification. In focal TBI models, cytotoxic edema has been suggested to be 
the prominent type of edema (Unterberg et al., 1997, Stroop et al., 1998), which was further supported 
by our ex-vivo MRI examinations, being highest immediately after trauma and then decreasing 
significantly over time (Barzo et al., 1997b, Marmarou, 2003). Vasogenic edema was seen in close 
proximity to the lesion cavity, as previously described (Kawamata et al., 2000, Maeda et al., 2003) and 
increased over time, albeit not significantly, which was perhaps due to the small sample size of the 
animal groups. Interestingly, there was a correlation between macrophage (ED1) accumulation and 
the presence of vasogenic edema. Perivascular macrophages in these areas (Rosenberg and Yang, 
2007), could perhaps exacerbate edema following TBI (Holmin and Mathiesen, 2000). In conclusion, 
we noted that rats subjected to hypoxia post TBI presented significantly increased lesion areas on 
MRI, however no significant difference between cytotoxic and vasogenic edema could be detected 
between the groups. 
Normoxic animals had higher expression of HIF1α in Paper V, which was more obvious at later time 
points (7 and 14 days). Paper V is the first study, to our knowledge that uses HIF1α in a model of 
hypoxic TBI, while up-regulation of HIF1α has been used to validate hypoxia-ischemic brain injury in 
neonatal rats (Li et al., 2007). In normoxic conditions, HIF1α correlated to apoptosis, has been 
analyzed in experimental TBI (diffuse and focal models) where an early increase (1 hour up to 3 
days), followed by a later decrease in expression, has been noted (Yu et al., 2001, Ding et al., 2009, 
Li et al., 2013). In our study, a similar temporal pattern of HIF1α was noted, even if Paper V also 
included later time points. An up-regulation of HIF1α does not necessarily mean that the injured tissue 
will perish. Even if it is recognized that HIF1α promotes apoptotic neuronal death (Singh et al., 2012), 
it has also been shown to up-regulate angiogenic factors (VEGF), erythropoiesis and act protectively 
against mitochondrial and cellular damage (Ebert et al., 1995, Liu et al., 1995, Lawrence et al., 1996, 
Fan et al., 2009). Perhaps, in hypoxic animals, the perilesional tissue die early after injury as 
supported by a greater neuronal loss, while the border zone in normoxic animals survive, hence being 
able to express HIF1α. This to some extent paradoxical finding is supported by two reviews, 
suggesting milder hypoxic states, HIF-1α triggers neuro-protective mechanisms, while more severe 
hypoxia promotes apoptosis and cellular death (Fan et al., 2009, Singh et al., 2012). In Paper V, HIF-
1α strongly correlated with VEGF activation (Liu et al., 1995) and like HIF-1α, VEGF was significantly 
upregulated in the normoxic animals, primarily 3, 7 and 14 days following injury, presumably 
highlighting the neuro-protective capabilities of HIF-1α. VEGF expression has been seen to peak 4-6 
days following TBI (Skold et al., 2005) and act as a promotor of neurogenesis after injury (Skold et al., 
2005, Skold et al., 2006), supporting its neuro-protective role (Thau-Zuchman et al., 2010). All in all, 
we do believe that up-regulation of HIF-1α and VEGF could reflect the neuro-protective capabilities in 
surviving cells, which could explain their increase in normoxia, and not in hypoxia, following TBI.  
IgG extravasation, C5b9-, ED1- and CD43 expression were not significantly different in the hypoxic 
compared to the normoxic rats in Paper V. This is the first CCI model of hypoxic TBI, to our 
knowledge, that analyzes tissue expression these proteins. These components of the immune system 
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all followed previously described temporal profiles; IgG (Beaumont et al., 2000) and C5b9 (Rostami et 
al., 2013) having an increased expression early after injury decreasing over time, while ED1 
expression increased over time (Bellander et al., 2010). CD43 expression was not significantly 
different to survival time. Studies that show a significant increase of ED1 (Hellewell et al., 2010) and 
IgG (Tanno et al., 1992) after brain injury in hypoxic conditions use diffuse TBI models, which are 
perhaps better suited for quantification since they do not present with a lesion cavity. 
We used female Sprague Dawley rats in Paper V, while previous hypoxic TBI-models have used male 
rats. It’s difficult to assess to what extent this presents as a limitation but it should be taken into 
consideration as the inflammatory response between male and female rats in experimental TBI is 
different (Gunther et al., 2015), presumably as females have shown better neuro-protective effects, 
which is suggested to be due to higher levels of estrogen and progesterone (Roof and Hall, 2000, 
McCullough and Hurn, 2003).  
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6 CONCLUDING REMARKS 
The general conclusions were that S100B, and NFL, contributed independently and significantly 
toward long-term functional outcome. Furthermore, repeated S100B sampling monitored patients by 
identifying secondary cerebral deterioration and the more global MD-CSF detected deranged cerebral 
metabolism. Finally, through a translational approach, we detected a trend for higher S100B levels if 
hypoxia was added to an experimental model of TBI.  
6.1.1.1 Paper I 
We concluded that serum levels of S100B add substantial information regarding patient outcome, in 
excess of that provided by age, GCS, pupil reaction and CT findings. In univariate analysis, late 
samples and AUC levels of S100B presented with a higher pseudo-R
2
 than all other analysed 
parameters toward long-term functional outcome. Elevated S100B levels are best correlated to CT-
findings and were not significantly correlated to extracranial injury. Samples acquired 12-36 hours 
after trauma have best correlation towards long-term outcome. 
6.1.1.2 Paper II 
Secondary peaks of serum S100B, 48 hours after TBI, are highly correlated with secondary 
radiological pathology. These secondary pathological findings on CT and MRI were found to be 
correlated to worse outcome in both uni- and multivariate analysis. We suggest increases of S100B 
≥0.05µg/L to be a monitoring trigger level prompting a review of the patient, displaying a sensitivity of 
80% and a specificity of 89% of detecting a secondary pathological progression of existing, or a newly 
developed, injury.  
6.1.1.3 Paper III 
We developed a new technique of “global” microdialysis monitoring of CSF and MD-CSF monitoring 
correlates with conventional CSF-levels of glucose and lactate. The MD recovery, using the current 
MD set-up in CSF, is close to 100% for both lactate and glucose which is higher than previously 
described. Increases in lactate and pyruvate, without any effect on the LPR, significantly correlate to 
unfavorable outcome, though perhaps indicating an effect of the presence of erythrocytes in the CSF, 
or possibly a hypermetabolic state in the injured brain.  
6.1.1.4 Paper IV 
We found that NFL levels in serum are significantly correlated to outcome even when adjusting for 
known strong predictors of TBI, including S100B. In line with its long half-life, logged NFL levels 
remained relatively unchanged over time, albeit with an upward trend, exhibiting limited intra-patient 
differences. No correlation between DAI, or CT findings, and NFL levels could be detected. We 
hypothesize that NFL might reflect a separate, more long term, pathophysiological process than 
current TBI biomarkers.  
6.1.1.5 Paper V 
We found that adding a hypoxic insult to a model of TBI using the CCI paradigm, it lead to a 
decreased neuronal survival, increased lesion size and a trend towards higher levels of the biomarker 
S100B in serum 1 day after trauma compared to normoxic animals. The levels of lactate and survival 
time when analyzed together provided a pseudo-R
2
 of 47% in determining the area of neuronal death, 
thereby highlighting the hypoxic effect on brain pathology. HIF-1α and VEGF were found upregulated 
following normoxic TBI, primarily at later survival times, perhaps indicating neuro-protective 
mechanisms.   
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7 FUTURE PERSPECTIVES 
In Paper I, we noted that S100B was an independent predictor of long-term functional outcome. We 
were not able to find a significant increase of registered extracranial trauma. However, as S100B has 
been detected in several extracranial tissues and have been shown to be elevated after extracranial 
injury, a more brain specific biomarker might perhaps further increase the explained variance towards 
long-term outcome (such as we did in Paper IV). Even if we monitored a substantial amount of clinical 
data, perhaps we would be able to better predict long-term outcome than the 35.9% pseudo-R
2 
that 
the core model (age, GCS, pupil responsiveness, CT-findings, hypoxia and hypotension at admission 
and S100B AUC) provided. In Paper I, perhaps if more monitoring data, including microdialysis data, 
cerebral oxygen saturation, intracranial pressure, perfusion pressure, hypotension and pyrexia, as well 
as other biomarkers of other cerebral origin was used, a better explained variance could be achieved. 
Also, pre-hospital morbidity probably represents a substantial part of the explained variance towards 
outcome and is something that is unfortunately lacking from many studies analyzing TBI and outcome. 
While GOS is somewhat of a golden standard in the field, its levels are a bit too wide and unspecific. 
Also, there is no clear cut line when it should be assessed, with studies ranging from hospital 
discharge to up to two years following trauma. Newer classifications, such as the eight graded scale 
extended GOS would perhaps better highlight aspects of functional outcome that are now missed. 
Also, a better and more regular and structured follow-up should be used to better assess outcome. 
This is important for all papers in this thesis. In Paper I, While we included samples up to 48 hours 
after trauma, being an arbitrary time-line that we thought represented the acute phase after TBI, later 
samples would perhaps have further improved outcome predictions and is something that has the be 
explored in future studies. 
In Paper II, while we correlated secondary peaks of S100B to radiological findings, but we cannot say 
if the peaks came before the deterioration or vice versa, neither was it possible to determine if the 
care or diagnostics provided lead to an improved outcome. This is something that has to be further 
explored in a prospective study, perhaps using even more frequent S100B monitoring than twice per 
day. In Paper II, we used a combination of MRI and CT scans. If a more regular follow up 
examinations, with repeated MRI scans the first week following injury, a better comparison between 
S100B dynamics and extent of structural damage could be assessed, such as in the upcoming 
multicenter Center-TBI study. The EUSIG (Edinburgh University Secondary Insult Grades) was used 
to grade different secondary insults in the NICU. While this system using different cut-offs (e.g. 20-
30mmHg, 30-40mmHg and >40 mmHg for ICP) a more individualized system, using the area under 
curve of each monitored secondary insult would perhaps provide a better and tailor-made monitoring 
of secondary burden and perhaps a better correlation towards outcome.  
In Paper III, we developed a new method of monitoring CSF using the MD technique. While we 
applied it on TBI patients, it’s entirely possible to use it on all patients where draining of CSF improves 
the clinical situation, such as patients suffering from subarachnoid hemorrhage. Another area where 
repeated sampling of lactate and glucose, through a closed system, is important is in acute bacterial 
meningitis where we believe that the published method would provide advantages to current 
monitoring methods. While we monitored the “conventional” metabolites using a 20 kDa MD probe, it 
would be possible to use the current system to extract larger molecules. Preferably, it would be able to 
monitor more brain specific proteins with a high temporal resolution. As mentioned, with the discovery 
of the glymphatic system, our method of global MD-CSF provides an important research platform in 
order to further validate the flow of proteins between different cerebral compartments with an 
increased temporal resolution. The major limitation of Paper III is the limited amount of patients and 
we hope that more patients will be monitored in this fashion in the future as to further validate the 
method. 
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In Paper IV, we found that NFL added significant and independent outcome information. We hope that 
future studies in the field of biomarker discovery have samples acquired in a more regular and 
constructed fashion with samples acquired from the same days, which would improve the discovery 
process. Also, other studies that have looked at outcome prediction at NFL levels have looked several 
weeks after the time of trauma, which is probably important if you are analyzing a protein with a long 
half-life or a biomarker that reflects an ongoing pathophysiological process. When assessing DAI, 
better methods are needed to quantify the extent of injury and perhaps in the future a more exact 
volume of disrupted axons would be able to improve the specificity and thus better validate the role of 
biomarkers of axonal origin. 
In Paper V, we showed that hypoxia exacerbates the lesion development in TBI. While we found an 
increased trend for S100B in hypoxic animals if sampled 24 hours after injury, perhaps there are 
better biomarkers to monitor this process which would provide a significant difference that should be 
explored in further studies. In vivo MRI would perhaps have increased the detection of injuries, 
including cerebral blood flow, which perhaps is altered following hypoxic injury. The method 
developed in Paper V could be used to validate the properties of different neuro-protective drugs and 
the biomarker profiles may work as templates to detect treatment effects, and thus be used as 
therapeutical targets.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Traumatiska hjärnskador är en mycket vanlig dödsorsak globalt och överlevande drabbas oftast av 
livslånga handikapp. Tidigare har främst yngre drabbats av svårare traumatiska hjärnskador. Nyare 
studier visar dock att allt fler äldre drabbas, vilket innebär en allt större belastning för en redan utsatt 
patientgrupp. Individer med allvarliga traumatiska hjärnskador, de som blir medvetslösa efter skadan, 
vårdas i respirator på specialiserade neurointensivvårdsavdelningar på landets universitetssjukhus. 
Vården fokuseras i dessa fall på att minimera risken för ytterligare skada av den redan drabbade 
hjärnan. För att veta vilka patienter som behöver prioriteras högt där man misstänker potentiellt 
livshotande hjärnskador, används i dag olika parametrar när man diagnosticerar såsom obefintlig 
pupillreaktion, dålig medvetandegrad, lågt blodtryck, låg syrgasmättnad i blodet samt hög ålder. 
Upprioritering av denna patientgrupp sker mot bakgrund av att utfallet för patienter med dessa faktorer 
är betydligt sämre vid långtidsuppföljning jämfört med andra patienter. Patienter som har drabbats av 
trauma och fått en blödning i hjärnan genomgår ofta kirurgi med utrymning av blodansamlingar samt 
inoperation av övervakningsutrustning som kan mäta tryck, syrgasnivåer samt ämnesomsättning i 
hjärnans vävnad för att motverka utvecklingen av ytterligare skador. Tyvärr är denna övervakning 
oftast mycket regional och kan därför inte ge en bild av hela den skadade hjärnan.  
Hjärnans nervceller och stödjeceller innehåller olika proteiner som man har kunnat påvisa frisätts vid 
skada. Dessa ämnen brukar kallas för biomarkörer och används inom flera medicinska områden för 
att fastställa och övervaka olika typer av biologiska processer i kroppen som ligger bakom skador och 
sjukdomstillstånd. En typ av stödjecell, så kallade astrocyter, innehåller höga nivåer av ett protein som 
heter S100B. Nervceller i sin tur innehåller höga nivåer av neuronspecifikt enolas (NSE) medan de 
trådliknande utskott som sammanbinder delar av hjärnan, axoner, till stor del består av neurofilament. 
Vid skada frisätts dessa ämnen i patientens blod och ryggmärgsvätska och kan då mätas för att 
bestämma omfattningen av hjärnskadan och ge en bredare bild än tidigare medicinska övervaknings- 
och diagnostiseringsmetoder.   
Genom tre olika databasstudier har vi studerat nivåer av biomarkörer samt koppla dessa till 
funktionellt utfall och allvarlighetsgrad av skada från 181, 250 respektive 265 patienter som vårdats på 
neurokirurgens intensivvårdsavdelning Karolinska Universitetssjukhuset i Solna mellan 2005 och 
2013. 
I den första studien som inkluderade 265 patienter ämnade vi fastställa hur nivåer av S100B vid 
ankomst till sjukhuset, och de följande 48 timmarna, kunde kopplas till utfallet 6 till 12 månader efter 
olyckan, samt fastställa tidpunkten för när man bör ta provet efter traumat för att få bäst koppling till 
utfall. Vi ville också se vilka faktorer som ledde till höga nivåer av S100B. Vi såg att förekomsten av 
serumnivåer av S100B bidrog signifikant till att förutsäga utfallet för patienten, mer än hög ålder, 
avsaknad av pupillreaktion samt låg medvetandegrad vid ankomst till sjukhus. De oberoende 
faktorerna för att förutspå utfall utöver nivåer av S100B var ålder samt pupillreaktion. Vi kunde genom 
studien fastställa att optimal tidpunkt för provtagning är 12-36 timmar efter trauma för att erhålla bäst 
koppling till utfall efter 6-12 månader. Enbart skador på hjärnan upptäckta med skiktröntgen kunde 
signifikant korreleras till förhöjda S100B nivåer. Skador vid olyckan i andra delar av kroppen 
resulterade inte i signifikant förhöjda nivåer av S100B i blodserum, vilket talar för att S100B är 
hjärnspecifikt.  
I den andra studien, innehållandes 250 patienter, ville vi se hur sekundära ökningar av S100B i serum 
48 timmar efter traumat gick att koppla till försämringar, eller nytillkomna skador, upptäckta vid 
datortomografi samt magnetkameraundersökningar. Vi ville även se hur dessa skadliga förändringar 
gick att koppla till utfallet 6-12 månader efter olyckstillfället. Genom studien fann vi en tydlig koppling 
mellan de patienter som haft sekundära stegringar av S100B i serum och där sekundära skador 
kunnat fastställas genom röntgen-, och magnetkameraundersökningar. Vi kunde även visa att dessa 
 60 
sekundära ökningar av S100B, samt skadeutveckling, signifikant bidrar till utfallet för patienter efter 6-
12 månader. En sekundär stegringsnivå redan på 0.05 µg/L är tillräcklig för att med god känslighet 
kunna detektera skadeutveckling på undersökningar, en nivå som är betydligt lägre än vad som 
redovisats i tidigare studier. 
I den tredje databasstudien som inkluderade 181 patienter där analys av neurofilament light (NFL) i 
blod (samt hos vissa även i ryggmärgsvätska) hade utförts ville vi se hur dessa nivåer enskilt kunde 
kopplas till långtidsutfallet, även i utfallsmodeller med S100B. Vi ville också se om graden av diffus 
axonal skada, en typ av hjärnskada som uppstår djupt i hjärnan som bara kan noteras på 
magnetkameraundersökning, kunde kopplas till nivåerna av NFL. Vi kunde fastställa att NFL 
signifikant bidrog till att förutspå utfallet, oberoende av nivåerna av S100B. Däremot kunde vi inte se 
någon koppling mellan diffus axonal skada eller annan hjärnskada noterad på datortomografi och 
magnetkameraundersökning av hjärnan och nivåer av NFL. Det förefaller vara så att nivåerna av NFL 
i blodet står för en kliniskt viktig skadeprocess som inte kan åskådliggöras med de metoder som finns 
tillgängliga idag. 
Vi har även försökt att förbättra mikrodialystekniken på en patientgrupp av 14 patienter. Mikrodialys är 
en tunn slang med hål där små ämnen kan passera. Genom att använda mikrodialys kan man få en 
överblick av hjärnans ämnesomsättning och cellsönderfall genom att mäta nivåerna av druvsocker 
(glukos), mjölksyra (laktat), pyrodruvsyra (pyruvat) samt glycerol (ett vanligt ämne i cellens membran). 
Genom att placera en mikrodialysslang i flödande ryggmärgsvätska som pumpas ut ur hålrummen i 
hjärnan, de så kallade sidoventriklarna, kan man mäta ämnesomsättningen i ryggmärgsvätska och på 
så sätt få en mer global bild av hjärnans status. Genom vår studie kunde vi konstatera att en god 
överensstämmelse mellan laktat- och glukosnivåerna mellan prover tagna med mikrodialysteknik 
jämfört med prover dragna från ventrikeldränaget med sedvanliga metoder, vilket säkerställer att 
metoden fungerar. Vi fann att patienter med ett sämre utfall 6 månader efter olyckan uppvisade 
signifikant förhöjda nivåer av laktat och pyruvat, vilket kan vara resultatet av en skadligt förhöjd 
ämnesomsättning, men även ett indirekt tecken på att det finns många röda blodkroppar i 
ryggmärgsvätskan. 
För att se hur en hjärnskada försämras vid låga syrgasnivåer, något som är relativt vanligt på 
olycksplatsen där den drabbades andning och luftvägar på olika sätt kan vara påverkade, användes 
en djurmodell för syrebrist och traumatisk hjärnskada. Råttor sövdes och fick inandas en 
syrgasblandning innehållande hälften av syrgaskoncentrationen i vanlig rumsluft efter att en 
traumatisk hjärnskada hade åsamkats över höger hjässlob.  
Gruppen av djur som inandades luften med låg syrgaskoncentration uppvisade lägre nivåer av 
syrgastryck samt högre nivåer av laktat vid blodgasprovtagning vilket bekräftade att djuren led av 
syrebrist (hypoxi). Dessa djur utvecklade ett större skadeområde vilket man påvisade med 
magnetkameraundersökning genomförd efter att djuren hade avlivats. Hjärnvävnaden undersöktes 
och resultaten visade att överlevnaden för nervceller var sämre för de hypoxiska djuren.  
Nivåerna av biomarkören S100B visade en trend till att vara högre i hypoxiska djur 24 timmar efter 
hjärnskadan, jämfört med nivåerna hos djur som inandades normal syrgaskoncentration. Vi kunde 
även se att nivåerna av proteinerna ”Vascular Endothelial Growth Factor, VEGF” som är inblandad i 
bildningen av nya blodkärl samt ”Hypoxia-Inducing Factor 1 Alpha, HIF1α” som kan uppreglera 
skyddande effekter i vävnad som utsatts för hypoxi, var signifikant förhöjda i djur som inandats normal 
syrgaskoncentration. Denna uppreglering skulle kunna indikera en skyddande effekt för den 
överlevande hjärnvävnaden, dock inte under extrema hypoxiska förhållanden vilket är förenligt med 
tidigare litteratur. I övrigt uppmätte vi delar av det medfödda immunförsvaret som har visat sig vara 
involverad i sekundära skadeprocesser i hjärnan i anslutning till skadan med hjälp av vävnadsanalys, 
så kallad immunohistokemisk teknik. Vi såg ingen signifikant skillnad för aktiviteten i det medfödda 
  61 
immunförsvaret mellan hypoxiska djur och de djur som inandats normal syrgaskoncentration. Med 
andra ord visar experimentet att hypoxi vid traumatisk hjärnskada leder till en mer omfattande skada 
för hjärnan som vi inte kan visa är signifikant medierad av immunförsvarets reaktion i hjärnan. 
Sammanfattningsvis har vi påvisat att biomarkören S100B är en stark prediktor för utfall vid traumatisk 
hjärnskada, framförallt om provet tas inom 12-36 timmar efter olyckan. Vi har även visat att nivåerna 
av S100B inom 48 timmar efter trauma ökar mest vid skada på hjärnan och inte vid skada på övriga 
kroppen. Vi har vidare funnit att S100B kan användas för att övervaka medvetslösa patienter efter 
traumatisk hjärnskada för att kunna detektera när det sker en utveckling, eller försämring, av en för 
utfallet relevant sekundär hjärnskada. Genom att addera mätningar av S100B till mätningar av NFL, 
en biomarkör med annat ursprung än S100B, har vi påvisat en signifikant ökning av prediktionen av 
det långtidsfunktionella utfallet för patienterna. Vi har även utvecklat och validerat en ny metod för att 
övervaka ämnesomsättningen med hjälp av mikrodialysteknik och kunskapen om att nivåerna av 
laktat och pyruvat är signifikant förhöjda hos patienter i ryggmärgsvätska vilket leder till ett sämre 
funktionellt utfall. Genom att använda en djurmodell för traumatisk hjärnskada har vi också kunnat 
konstatera att hypoxi leder till en sämre överlevnad för nervceller samt en större skada i hjärnan. Vi 
har vid försöken noterat en trend till högre S100B-värden hos hypoxiska djur efter 24 timmar från 
skadetillfället vilket indikerar att biomarkören är användbar för att se om syrebrist har förvärrat en 
hjärnskada.  
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